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1 Introduction 
1.1 Frequency and development of cancer  
Cancer is one of the four main types of chronic, so called noncommunicable diseases 
(NCD). Altogether 38 million people worldwide die from such diseases, summing up to 
68% of all death in 2012. The mortality from cancer was 8.2 million people worldwide in 
that year. Only cardiovascular diseases accounted for more NCD death. In the upper-
middle to high-income countries, cancer is still amongst the top ten killers (Figure 1) [1, 2].  
  
Figure 1: Top10 causes of death in upper-income countries worldwide 
The ten leading causes of death by the globally two highest income groups [2]. Liver-, stomach-, and breast 
cancer highlighted in red boxes belong to this Top10. 
The reason for the high incidence of cancer becomes clear when differences between 
high- and low-income countries (Figure 2, p.9) are compared. Apparently, the cause of 
death is mainly related to hygiene and life expectancy. In high-income countries like 
Germany or the United States, individuals above 70 years account for seven of ten deaths, 
while only one in hundred children under the age of fifteen years dies. In contrast, in low-
income countries like Somalia or Tanzania, only two of ten deaths concern individuals 
above seventy years, while four of ten deaths occur among children below fifteen years. 
Such children mostly die of infectious diseases or complications during childbirth [2]. With 
an average age of 69 years every second person in Germany will have been diagnosed for 
cancer (“cancer incidence”), involved are 51 % of the male and 43 % of the female 
population. Half of these cancer patients will die due to the disease (“cancer mortality”). 
This sums up to every fourth man and fifth woman of the entire German population [3]. 
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Figure 2: Country income groups 
Economies with populations of more than 30,000 were used for operational and analytical purposes. They 
are divided among income groups according to 2010 gross national income per capita [4]. 
The most prominent cancers in Germany are prostate or lung cancer for men, and breast- 
or intestinal cancer for women (Figure 3) [5]. 
 
Figure 3: Cancer incidences in Germany 
The most frequent tumor sites as a percentage of all new cases of cancer in Germany 2010 [5]. 
Importantly, the number of new cases of cancer increased up to 21 % for males and 14 % 
for females between the years 2000 and 2011 in Germany. Here, the demographic change 
is considered to be the main factor for such augmented cancer incidences [6]. Individuals 
of higher age i.e. with a longer life span exhibit a higher chance to acquire mutational 
changes within their cells that finally lead to cancer. 
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In order to systemize knowledge on cancer development and cancer death, ten so-called 
hallmarks were formulated by Hanahan and Weinberg [7] to explain the mutational switch 
from normal cells to a neoplastic phenotype, resulting in malignant tumor cells (Figure 4): 
 
Figure 4: Hallmarks of cancer 
Normal cells can be transformed into malignant variants by acquisition of the presented capabilities and 
enabling characteristics [7]. 
In the following paragraph, the ten hallmarks of cancer are described in short detail: 
 
 The most obvious property of cancer cells is their ability of unrestricted growth and 
proliferation. 
 Under normal circumstances tumor suppressor genes inhibit abnormal cell growth, 
but cancer cells are not susceptible to the released anti-growth signals. 
 To continually grow, tumor cells are furthermore resistant to the induction of 
programmed cell death, called “apoptosis”. 
 Cancer cells are able to exceed the intrinsically predefined number of cell cycles that 
normally results in growth termination of viable cells by maintaining the length of 
telomeres at the end of the chromosomal DNA. 
 To ensure a sufficient supply with nutrients and oxygen once they surpass a certain 
size, tumors develop their own neovasculature system, a process which is called 
“angiogenesis”. 
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 By the “metabolic switch” cancer cells gain energy by aerobic glycolysis to ensure the 
unrestricted availability of glycolytic intermediates for the biosynthesis of new cellular 
components. 
 Immunogenic cancer cells are able to evade “immune surveillance”, the ubiquitous 
function of the host´s immune system to detect and eradicate neoplastic and pathogenic 
cells. 
 Tumor cells are able to migrate from their primary localization to new niches in the 
body. There they can establish further cell assemblies called “metastases”, which are 
responsible for the majority of human cancer deaths [8]. 
The acquisition of the described functional capabilities of cancer cells to enable growth, 
survival and dissemination are based on two fundamental cell characteristics: 
 The genome integrity of cancer cells is altered compared to normal cells. Mutations 
occur especially in such genes that favor the onset of neoplasia [7] and thereby the 
possibility to selectively outgrow the cellular colony. 
 The tumor microenvironment, which contains innate and adaptive immune cells, 
releases growth-, survival-, and pro-angiogenic factors that support tumor growth and 
facilitate cancer cell mutations. 
 
1.2 The tumor microenvironment 
The development of a tumor is not only dependent on the malignant cells themselves, 
they also need a supportive microenvironment. This consists of different cell types of the 
immune system, as well as of mesenchymal cells forming the tumor-associated stroma. 
When they start to develop, tumors take up nutrients from their close environment. 
During the exponential growth phase of the tumor, the need for oxygen is especially high 
and amounts to 3 - 7 % of oxygen concentration [9]. However, during growth progression 
the tumor diameter increases (Figure 5, p.12) and cells of the inner part of the tumor 
receive insufficient amounts of nutrients and oxygen by the diffusion processes. In this 
avascular phase of growth, the tumor proliferation is therefore counterbalanced by cell 
death and chronic hypoxia [10]. Hypoxic tumors have 1 % or less of oxygen available, 
which promotes cell death by apoptosis or necrosis [9]. 
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Over the developmental process, the occurrence of such hypoxic regions inside solid 
tumors is transient and locally instable. Under hypoxic conditions, tumor cells react by 
activating the transcription factor hypoxia-inducible factor-1α (HIF-1α) [11, 12]. As 
consequence, cancer cells start to transcribe and secrete angiogenic factors like vascular 
endothelial growth factor (VEGF) or basic fibroblast growth factor [13, 14]. These 
cytokines activate the proliferation and mobilization of endothelial cells from already 
existing normal blood vessels to from a tumor neovasculatur, a process called “tumor 
angiogenesis” (Figure 5) [15]. This results in an appropriate supply of energy and oxygen in 
all malignant cell layers. 
 
Figure 5: Developmental steps during tumor progression 
The developmental processes from a single mutated cancer cell to an exponentially growing tumor require 
certain metabolic switches of the tumor cells. To ensure appropriate supply of energy and oxygen, tumor-
associated blood vessels are formed by the tumor itself through the secretion of pro-angiogenic cytokines. 
An event defined as “angiogenic switch” [16]. 
However, the novel tumor-associated blood vessels have an abnormal structure due to a 
loose attachment of pericytes [17]. This leads to leakiness of the vessels and might cause 
irregular, temporally obstructed, or dysfunctional blood flow [10]. To counteract the 
resultant development of huge hypoxic areas within the tumor, the secretion of pro-
angiogenic proteins is further upregulated within the whole tumor microenvironment to 
enhance neovascularization [16].  
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Not only the tumor cells, but for instance also neutrophils as part of the tumor 
microenvironment (Figure 6, p.13) can stimulate angiogenesis via secretion of matrix 
metallopeptidase 9 (MMP-9 / gelatinase-B) function and activation of VEGF [18]. Such 
inflammatory reactions by immune cells are considered to favor tumor growth 
progression and dissemination [10, 19].  
In the last decade it became obvious, that the ongoing attraction of immune cells like 
neutrophils, macrophages, myeloid-derived suppressor cells (MDSCs) or regulatory T cells 
(T regs) by cancer cells facilitates tumor growth progression by the establishment of an 
immunosuppressive environment [20, 21]. Preceding such findings, the immune system 
was believed to exclusively exert immune surveillance, i.e. the prevention or rescue from 
cancer. Now a more complex situation starts to appear. A recent review of Joyce and 
Pollard [20] illustrated the main effector cells of the innate and adaptive immune system 
for tumor development (Figure 6): 
 
 
Figure 6: The tumor microenvironment 
Primary tumors consist of cancer cells surrounded by a network of different cell types. This tumor 
microenvironment includes cells of the innate and adaptive immune system, endothelial cells, and stromal 
fibroblasts. Cells originating from the bone marrow (BMDC) include myeloid-derived suppressor cells 
(MDSC), TIE2-expressing monocytes (TEM), and mesenchymal stem cells (MSC) [20]. 
In the following paragraph, tumor-infiltrating cells that are important for the present 
study are described in short details: 
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 Neutrophils are CD11b+ Ly6G+ cells and defined as tumor-associated neutrophils 
(TANs) once they infiltrate cancerous tissues. Fridlender et al. [22] described different 
activation states of TANs. They characterized the distinct end-staged phenotypes as “N1” 
for neutrophils with anti-tumorigenic properties and “N2” for neutrophils with pro-
tumorigenic functions. N1 TANs release e.g. increased amounts of pro-inflammatory 
cytokines to activate additional cells in the microenvironment. Furthermore, they have a 
higher capacity to directly kill tumor cells via superoxide or H2O2 secretion, and can 
activate cytotoxic T cells (CTLs) to destroy tumor cells [22]. N2 neutrophils on the other 
hand are for instance able to support tumor development [23] via an increased 
production of arginase that inhibits immune cells, and pro-angiogenic factors like VEGF. 
Besides, they exhibit downregulated cellular cytotoxicity [22]. Further information on 
TANs is highlighted in the chapter below. 
 Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of 
immature cells, progenitor cells, and mature myeloid cells [23, 24]. They are generally 
defined as a CD11b+ and Gr1+ (this antibody binds to LyG+ and Ly6C+) cell population 
consisting of two main, functionally similar cell types: monocytic MDSCs (M-MDSCs) 
defined as CD11b+ Ly6Chigh Ly6G- and granulocytic MDSCs (G-MDSCs) classified as 
CD11b+ Ly6Clow Ly6G+ [25, 26]. M-MDSCs resemble G-MDSCs also in their phenotype [27]. 
Depending on the tumor-derived factors, MDSCs inside the tumor microenvironment can 
develop into several myeloid cell subsets with the general task to suppress immune 
functions [25, 28]. This mainly concerns the suppression of proliferation of effector T cells 
by the secretion of the cytokines transforming growth factor-β (TGF-β) or interleukin-10 
(IL-10) [23, 25]. MDSC subsets with an identical purpose occur also in bone marrow (BM), 
blood, spleen and liver [29].Immature MDSCs can mature into CD11b+ Gr1- F4/80+ tumor-
associated macrophages (TAMs) or CD11b+ Gr1- CD11c+ dendritic cells (DCs) [30]. A clear 
characterization of such at least seven CD11b+ tumor-infiltrating subsets is not possible 
until today due to a lack of unique markers [28, 31].  
MDSCs and N2 TANs do not only share cell surface molecules. They also show identical 
phenotypes according to cell morphology or biomarker expression. They additionally 
perform similar functions with respect to angiogenesis, tumor-supporting activities and 
cell recruitment [27]. Both belong to a low-density neutrophil subpopulation [32], which is 
present in mice and humans [33, 34]. The discussions about a distinction of G-MDSCs and 
N2 neutrophils into two separate cell populations most likely arose because of the fact, 
that MDSC and neutrophil research was performed in separated research communities 
[35]. No specific marker reliably distinguishes immunosuppressive N2 neutrophils from G-
MDSCs [20, 35]. 
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Therefore, these two cell phenotypes represent morphologically distinct neutrophil 
subsets within a continuum of differential phenotypes in tumor-bearing mice [32, 35]. 
Sine MDSCs are immature precursors of neutrophils [36], G-MDSCs can [30, 35] and will in 
the following be considered as an immune-suppressive status of neutrophils. 
 Tumor associated macrophages (TAMs) are CD11b+ F4/80+ myeloid cells, which can 
also be separated into two functionally distinct phenotypes. Classically activated “M1” 
TAMs are able to directly kill tumor cells or stimulate anti-tumor functions in T cells. 
Alternatively activated “M2” TAMs suppress the anti-tumor immunity of the tumor 
microenvironment [25]. Like reported for TANs, the TAM-population also contains cells of 
the MDSC pool [29]. 
 CD4+ and CD8+ T cells infiltrate tumors as well during the developmental process. 
Within the CD4+ lineage, T helper (Th) 1 cells function as helpers for tumor rejection by 
stimulating cytotoxic CD8+ T cells. T regs on the other hand suppress activities of the 
immune system, especially CD8+ T cells and natural killer cells functions [37, 38]. Cytotoxic 
CD8+ T cells are very important for the anti-tumor activity of the immune system, because 
these effector cells can destroy cancer cells through granzyme B- and perforin facilitated 
apoptosis [39]. 
For the present study, the function of neutrophils and T cells within the tumor 
microenvironment was of main interest. Therefore, these cell types will be described in 
more detail in the following chapters. 
 
1.2.1 Neutrophilic Granulocytes 
1.2.1.1 Activation and function 
Neutrophils belong to the cellular part of the innate immune system and represent one 
kind of phagocytic cell. Originating from hematopoietic stem cells in the BM, they mature 
under the influence of the hematopoietic growth factors granulocyte colony-stimulation 
factor (G-CSF), and granulocyte-macrophage colony-stimulation factor (GM-CSF) which 
also stimulates monocyte development [40]. Neutrophils are the first cells of the innate 
immune system that migrate to sides of infection or inflammation to perform their pro-
inflammatory functions [35, 41]. These include (i) phagocytosis, (ii) the release of cytotoxic 
granular contents including proteases, anti-microbial peptides (AMPs), or proteins like 
myeloperoxidase (MPO), and (iii) the destruction of cells in their environment [42].  
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The latter is performed by the release of reactive oxygen species (ROS) like O2
-, H2O2, 
HOCl, and OH, or nuclear contents as the major component of neutrophil extracellular 
traps with attached proteases and AMPs [35, 43-45]. Neutrophils are able to recognize 
invading pathogens e.g. via pathogen recognition receptors. These receptors, that include 
Toll-like receptor (TLR) 4 or TLR5, bind to pathogen-associated molecular patterns 
(PAMPs), like lipopolysaccharide (LPS) or flagellin [39], respectively. Additionally they 
recognize damage-associated molecular patterns (DAMPs), which are uncontrollably 
released by tumors, as well. Therewith, neutrophils are recruited into the tumor 
microenvironment [46]. 
Further neutrophil receptors which are important for the immigration into tumors are the 
chemokine receptors CCR1, CCR2, CXCR2 and CXCR4 [47-49]. The chemotactic migration 
of neutrophils is activated after binding of a receptor´s agonist. Such chemokines can be 
secreted by various immune and epithelial cells, but also tumor cells themselves can 
mediate recruitment of neutrophils via an increased expression of neutrophil attracting 
chemokines [40, 50]. Murine tumors secrete for example CCL-3 / MIP-1α (macrophage 
inflammatory protein 1 alpha), CXCL-1 / KC (keratinocyte chemoattractant), and CXCL-
2 / MIP-2 (macrophage inflammatory protein 2) [22, 51]. All chemokines have besides 
their systematic names (CCL/CXCL) also names which were derived from the original 
discovered function. These give most of the times a more detailed understanding of the 
chemokine´s functions. Hence, both names will be used in the present study for optimal 
notations of the tumor microenvironment.  
Due to their receptor repertoire, neutrophils have a high chance to migrate into tumors 
and perform their pro-inflammatory functions in this tissue. However, because of the 
already mentioned abnormal structures of the tumor-associated blood vessels, the tumor 
microenvironment exhibits gradients of oxygen [52]. Nevertheless, such TANs are able to 
fulfill their function under low oxygen conditions. They carry out a metabolic switch that 
results in a metabolism primarily based on glycolysis [53, 54]. Since their cytotoxic 
functions are unaffected by that, neutrophils rapidly die via apoptosis in the tumor, as 
they are well known as short-lived cells [35, 55]. However, recently it was shown that 
TANs have multiple phenotypes [35]. One characteristic is a prolonged survival time, 
extended from the familiar half-life of 7 hours up to 5.4 days [56, 57]. A prolonged life 
span enhances the possibility for such cells to change their phenotype in accordance to 
their environment and the required functions [35]. Together, due to the phenotypic 
specialization, neutrophils acquire the possibility to fulfill either pro- or anti-inflammatory 
immune functions, based on the type, combination and concentration of released 
cytokines in their environment [58]. 
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1.2.1.2 Characterization of tumor-associated neutrophils 
Out of the pool of hematopoietic cells, neutrophils are identified by a high expression of 
the markers CD11b and Ly6G [22]. When approaching an inflammatory site, neutrophils 
start to roll via interactions of the selectin CD62L with appropriate ligands on endothelial 
cells [59]. They then migrate to the site of function using the integrin CD11b [60, 61]. In 
accordance, upon maturation and activation CD62L is downregulated, whereas the 
expression of CD11b is upregulated [59].  
The protein Ly6G, whose functions still needs to be characterized [62], is expressed from 
low to high levels by neutrophils, and is reported to be present also at a low level on 
eosinophils as well [62]. But the identification of tumor infiltrated cells by Ly6G is 
exclusively limited to neutrophils [36] and routinely used in research [22, 63-65]. 
However, the actual literature displays a controversy about the expression and intensity of 
a third protein “Ly6C” by neutrophils, with definitions ranging from Ly6C- [66] over  
Ly6C-/int [67], LyCint [28] or Ly6Clow [68], to Ly6C+ [23]. Ly6C is also expressed by DCs and 
some cells of the CD4+ and CD8+ lineages. Currently it is used to distinguish inflammatory 
monocytes from residential monocytes [62]. In the present work, neutrophils are reliably 
characterized on the basis of their CD11b+ and Ly6G+ expression.  
In addition to these two surface molecules, the literature uses plenty of further markers 
and genes to describe the phenotypical specialization of neutrophils (Table 1, p.18). The 
transient phenotype of tumor-associated neutrophils is influenced by the neighboring 
cells and soluble molecules within the tumor microenvironment. These parameters 
change during the process of tumor development. In the early and pre-clinical stage 
(Figure 5, p.12), the immune system is able to control the growth of cancer cells. In this 
phase of cancer control, many inflammatory processes are activated within the tumor 
microenvironment, which favor the induction of pro-inflammatory neutrophil functions 
and a consequent specialization into N1 TANs. Cytokines which support such tumor-
suppressing activities in TANs are for example interferon-β (IFN-β), interferon-γ (IFN-γ), 
and GM-CSF [69, 70]. Whereby the type I interferon IFN-β is probably the trigger 
responsible for the induction of the tumor-suppressing N1 phenotype (Figure 7, p.19) [48, 
51, 71]. Such N1-specialized cells show an increased capacity to migrate into tumors by an 
upregulation of cell adhesion molecules like CD11b [60]. Furthermore, specific cytokines 
or chemokines like tumor necrosis factor-α (TNF-α) or IFN-γ guide the extravasation of the 
cells out of the blood vessels into the tumor tissue [60]. Also the protein FasL, which can 
be expressed on epithelial cells as well as on tumor cells, supports neutrophil infiltration 
into cancerous tissues [72]. In addition, the interaction of FasL and its receptor Fas on 
neutrophils regulates the cells´ lifespan via the induction of apoptosis [73].  
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This process is induced after FasL-Fas interaction and the resulting activation of the Fas 
receptor. Thereby the death receptor-induced apoptosis pathway is stimulated. This leads 
to the activation of caspase 8, which then further activates the effector caspases 3 and - 7. 
Cell death is the final outcome [74]. Since N1 TANs have a shorter life time as N2 TANs, 
they can be identified by an upregulation of Fas and active caspase 3 [22, 75]. Extrinsic 
receptor-induced pathways triggering apoptosis can also be induced in other cells within 
the tumor microenvironment. Therefore, neutrophils release large amounts of pro-
inflammatory cytokines like TNF-α or IL-1 [40]. The secreted TNF-α has cytotoxic functions 
on for example the tumor neovasculature which exhibits increased numbers of the TNF-α 
receptor-1. The activation of the receptors for TNF-α results in hyperpermeability of the 
already leaky tumor-associated blood vessels and huge amounts of erythrocytes and other 
circulating cells are able to extravasate into the tumor tissue, resulting in a massive 
hemorrhagic necrosis of the tumor [76, 77].  
Table 1: Overview of neutrophil phenotyping markers 
The following cell surface molecules, cytokines, chemokines, enzymes and substances are used to 
distinguish functional phenotypes of tumor-associated neutrophils. 
Type of biomarker Biomarker Characterization of neutrophil polarization as 
  N1 
tumor-suppressive 
N2 
tumor-supportive 
Cell surface molecule Icam (CD54) X [22]  
 Fas (CD95) X [22]  
 CD62L (L-selectin)  X [78] 
 CXCR2  X [48] 
 CXCR4  X [51] 
Chemokine CCL-2 / MCP-1  X [22] 
 CCL-3 / MIP-1α X [22]  
 CCL-5 / RANTES  X [22] 
 CCL-17 / TARC  X [47] 
 CXCL-1 / KC  X [48] 
 CXCL-2 / MIP-2  X [48] 
 CXCL-5 / ENA-78 X [48]  
Cytokine Active caspase 3 X [75]  
 G-CSF  X [79] 
 GM-CSF X [22]  
 TNF-α X [22]  
 VEGF  X [51] 
Enzyme Arginase  X [22] 
 MMP-9/ gelatinase-B  X [22] 
Substance iNOS X [47]  
 ROS X [22]  
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Besides killing of tumor cells within the tumor microenvironment, N1 TANs can also 
interact with further immune cells. Neutrophils of N1 phenotype are for example 
characterized by an increased presentation of intercellular adhesion molecule-1 (Icam-1 or 
Icam) on their surface [51]. By that, TANs can receive immunoregulatory signals from 
T cells. Their lymphocyte function associated antigen-1 binds to Icam [80]. At the same 
time, the T cell can receive stimulatory signals from the antigen-presenting neutrophil 
possibly via the T cell receptor (TCR), and co-stimulatory molecules like cluster of 
differentiation (CD) 80 and CD86 which bind to CD28 on the T cell surface. 
Since some antigen-presenting cells (APCs) lack the expression of appropriate CD28 co-
stimulators, alternative co-stimulatory ligands like Icam can perform important roles 
during cognate interaction [81]. Especially when antigen is limited like in tumors with low 
immunogenicity, Icam leads to an accumulation of major histocompatibility complex 
(MCH) molecules, which increases the chance for antigen presentation and T cell 
activation [81]. By that, N1 TANs can contribute to tumor-inhibitory processes within the 
tumor microenvironment. 
 
Figure 7: Cytokines causing neutrophil polarization in tumors 
The switch of neutrophils between the two end-stage functional phenotypes “N1” and “N2” are guided by 
the cytokines TNG-β and IFN-β [51]. 
On the other hand, aged and clinical detectable tumors (Figure 5, p.12) consist of cancer 
cell-accumulates that were able to escape the immune system and started to establish an 
immunosuppressive microenvironment favoring tumor growth progression. Such cancer 
cells secrete VEGF, TGF-β, galectin, or indoleamine-2,3-dioxygenase (IDO) [82]. TGF-β 
activates tumor-supporting functions in TANs and induces a phenotypic switch from 
tumor-suppressing N1 TANs to pro-tumorigenic N2 TANs (Figure 7) [32, 47, 51]. By that, 
tumors exploit the plasticity of TANs and manipulates them to support tumor growth [19].  
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Further environmental conditions which favor the activation of tumor-supportive 
functions in TANs are the hypoxic conditions inside the tumor and the cytokines G-CSF, IL-
4, IL-10, IL-17 and CCL-2 [70, 83]. Neutrophils with an N2 phenotype can (i) produce 
various cytokines which positively influence hematopoiesis, angiogenesis, and 
fibrogenesis, thereby promoting further tumor escape mechanisms [58], (ii) release 
elastase which supports cancer cell proliferation when taken up by tumor cells [84], or (iii) 
secrete the hepatocyte growth factor, upon stimulation with tumor derived cytokines like 
GM-CSF, to directly favor migration of cancer cells and thereby promoting tumor growth 
and dissemination [85]. In addition, activated N2 TANs are able to (iv) downregulate their 
own apoptotic and cytotoxic functions [78], (v) suppress the activities of effector T cells by 
the secretion of nitric oxide synthase type 2 [86, 87], or (vi) inhibit cytotoxic CD8+ T cells 
responses via arginase secretion.  
The impact that different functional phenotypes of TANs might have on tumor 
development is presently in research focus and is still emerging [51]. Nevertheless, it is 
quite accepted that at least the two cytokines TGF-β and IFN-β trigger phenotypic 
switches of neutrophils within tumor microenvironments (Figure 7, p.19). 
 
1.2.2 Functions of tumor-infiltrating T-lymphocytes 
Most solid tumors contain also T cells within their microenvironment, which are defined 
as tumor-infiltrating lymphocytes (TILs). Like for TANs, the cytokine milieu inside the 
tumor is responsible for the attraction of TILs. The general differentiation of CD4+ T cells 
into different subsets is mainly influenced by the cytokine milieu present at the initiation 
site of T cell activation i.e. in immune inductive sites like lymph node or spleen. Whereas 
IFN-γ and IL-12 induce the development of Th 1 cells, IL-4 favors the proliferation of Th 2 
cells [39]. A combination of the cytokines IL-2 and TGF-β polarizes CD4+ T cells into T regs, 
IL-6 and TGF-β induce Th17 cells, and IL-6 together with IL-21 favors the development of 
T follicular helper cells [88]. Th 1 cells are important for the priming of CD8+ T cells and 
enable their proliferation by the release of IL-2 and IFN-γ [39]. The CTLs are able to kill 
cancer cells by the release of lytic proteins and expression of FasL. The three secreted 
cytotoxic effector molecules perforin, granzyme, and granulysin are stored in lytic 
granules that are discharged upon recognition of the cognate antigen on the tumor cell 
[39]. In the pre-clinical stage of tumor development, APCs can present tumor-derived 
antigens of immunogenic cancer cells via their MHC class I - or MHC class II - molecules to 
naïve T cells in peripheral lymphoid organs [39]. This results in the activation and 
differentiation of such T cells.  
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After maturation within the lymph node, the effector CD4+ and CD8+ T cells migrate to 
their antigen-target via the circulation, guided for example by upregulation of CXCR-3. By 
that, they can be triggered by CXCL-9 / Mig (monokine induced by gamma-interferon) and 
CXCL-10 / IP-10 (IFN-γ-inducible protein 10) which are produced inside tumors [89]. Via 
the functions of such activated effector T cells, tumors can be cleared completely. The 
existence of cancer cell antigens, which distinguish the neoplastic cells from their normal 
counterparts, is therefore very important for a successful anti-tumor immunity executed 
by T cells. However, tumors are able to use such T cell properties for their own purposes, a 
process called cancer immunoediting. For example, tumor antigens which are often either 
products of mutated genes like p53 or over-expressed normal antigens like human 
epidermal growth factor receptor 2, can lead to immunological T cell tolerance or anergy, 
when presented to the T cell without a co-stimulatory signal in addition [82, 90]. 
Another possibility of cancer immunoediting is the development of cancer cell variants. 
Such cells arise due to immunological pressures, and use their neoplastic properties of 
genetic instability and unrestricted proliferation to evade activities of the immune system 
by for example a loss of tumor-specific antigens [19, 91]. A further way of tumor cells to 
block functions of tumor-inhibitory T cells is to increase (i) the number of 
immunosuppressive cells in the tumor microenvironment like T regs, or (ii) the presence of 
immune inhibitory cytokines like TGF-β or (iii) immunosuppressive cancer cell ligands like 
programmed cell-death ligand 1 (PD-L1) [92, 93]. But also the co-stimulatory ligands CD80 
and CD86 on APCs can contribute to an inactivation of CTLs by binding to the cytotoxic  
T-lymphocyte late antigen (CTLA)-4 on activated CD8+ T cells [92]. All these escape 
mechanisms of cancer contribute to the progressive development from a small cancer cell 
accumulate to a clinically detectable tumor. 
 
1.3 Cancer therapies 
1.3.1 Immunotherapy 
Besides the well-established therapies against cancer (surgery, chemo-, and radiation-
therapy), new targeted cancer immunotherapies were developed recently. One promising 
immunotherapy that is forwarded very strongly is the adoptive CD8+ T cell therapy. Here, 
TILs e.g. already specific against tumor-associated antigens (TAA) are isolated, expanded 
in number, and re-injected into the patient [91]. Because such tumor-reactive TILs are 
originally very low in number and difficult to isolate [94], further strategies for cancer 
therapy by T cells were designed (Figure 8, p.22).  
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Therapeutic targets for that are molecules and cytokines which are used by solid tumors 
to suppress immune responses. For instance, CTLs which are reactive to IDO, a molecule 
expressed by cancer cells to induce immunosuppression and neutrophil apoptosis [95, 96], 
or T cells resistant to the immunosuppressive cytokine TGF-β are propagated [97]. 
Another possibility is to block the accumulation of immunosuppressive T regs by the use 
of anti-CD25 monoclonal antibodies [91]. A further strategy of molecular targeting is the 
administration of monoclonal antibodies that directly block CTL-inhibitory signals, like the 
commercially available drugs ipilimumab or nivolumab. Ipilimumab is a human 
monoclonal anti-CTLA-4 antibody that blocks the upregulated inhibitory molecule able to 
bind to CD28 on T cells [98]. It is used to treat melanoma, prostate-, lung-, and kidney 
cancer [91, 99-103]. Nivolumab is an anti-PD-1 antibody which prevents the inactivation of 
T cells via binding of PD-L1 expressed by tumor cells [104] (Figure 8, p. 22), and showed in 
up to 28 % of patients responses against melanoma, renal-cell carcinoma, and non-small-
cell lung carcinoma [91, 105].  
 
Figure 8: Molecular targeting via monoclonal 
antibodies increases CTL activity in tumors 
The monoclonal antibodies PD-1, anti-IDO, and 
anti-CD25 are able to block the inhibition of 
tumor-infiltrated CTLs and the recruitment of 
immunosuppressive T regs into the tumor 
tissue [92]. 
Monoclonal antibodies (mAbs) are also used to link neutrophils to cancer cells (Figure 9). 
This can occur by chance via the free Fc domain of a designed cancer cell-specific mAb 
that can be targeted by the IgG Fcγ-receptors of neutrophils. By that, the cells are able to 
recognize and most likely to phagocytose the mAb-opsonized tumor cells, as TAMs do 
[106]. The induction of tumor cell death by autophagy or necrosis are additional 
mechanisms supposed to be induced by neutrophils, but the exact killing mechanism is 
still unknown [106, 107]. Alternatively, bi-specific mAbs can be used, which directly link 
neutrophils to the target tumor cells.  
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The cytotoxic functions of the neutrophils will subsequently be activated, resulting in 
tumor destruction. For example the bi-specific mAb against CD89 and human leukocyte 
antigen (HLA) -class II enables the lysis of HLA-class II expressing malignant B-lymphoid 
cells by activated neutrophils [108]. 
 
Figure 9: Monoclonal antibody-
induced activation of TANs 
The designed IgA mAb specifically 
binds to tumor cells. Its free Fc 
domain links TANs to the target 
cancer cell. Thereby the cell gets 
activated and secretes pro-
inflammatory cytokines (IL-1β and 
TNF-α) or facilitates the 
recruitment of further N1 TANs by 
Leukotriene B4 (LTB4) secretion or 
CXCL-8 production by endothelial 
cells [106]. 
Importantly, the ongoing investigations on immunological functions of cells within the 
tumor microenvironment will provide many novel molecular targets for new 
immunotherapeutic strategies [92]. Additional strategies to activate / stimulate the 
immune system against the tumor are the administration of auto-reactive effector cells 
[109], vaccinations against TAAs with viral-based vectors [110], or the administration of 
bacteria [111, 112]. 
 
1.3.2 Bacteria-mediated tumor therapy 
The first attempts to use bacteria systematically for tumor therapy go back to the turn of 
the 19th to the 20th century [113]. The American physician William Coley started these 
studies based on previous episodic approaches, which demonstrated the induction of 
tumor regression after the application of bacteria. Therefore, he treated his patients 
suffering from ulcerated tumors with a mixture of inactivated Streptococcus pyogenes and 
Serratia marcescens [114]. The application of this so called “Coley´s toxin” led to tumor 
clearance in many of the treated patients [114, 115]. He explained the effect as a systemic 
action probably induced by toxic products of Streptococcus pyogenes.  
Today we know that he activated the immune system of the patients by the intratumoral 
injection of his toxin and induced an anti-tumor immune effect [115]. This therapy did not 
yield general acceptance and became ignored for almost 100 years. Recently, this concept 
was resurrected and many bacterial species have been shown in animal models to target 
solid tumors and retard their growth [111, 116, 117]. 
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Nowadays, for safety reasons many bacteria were attenuated or inactivated to be 
applicable for tumor therapy. The Mycobacterium bovis strain Bacillus Calmette-Guerin is 
for example used today as an immunotherapeutic intravesical agent for relapse inhibition 
of bladder cancer [118]. Moreover, glioblastomas are successfully destructed in rats by 
the intravenous application of Clostridium novyi-NT spores [119]. Nevertheless, the 
mechanisms of the anti-tumor effect by Clostridia is restricted to the anaerobic areas of 
the tumor tissue and so far poorly understood [120]. A further commonly used bacterium 
at present is Salmonella enteric serovar Typhimurium (S. Typhimurium). By the 
intravenous application of the bacteria into tumor-bearing mice, a dramatic cytokine 
storm of pro-inflammatory mediators is induced. Among such cytokines are IL-1β, VEGF, 
TNF-α, and IFN-α, which have the primary function to promote further activities of the 
immune system [121]. Additionally, TNF-α activates the release of nitric oxide by 
endothelial cells, which results in vasorelaxation and a slowdown of the blood flow. As the 
most probable active compound elicited by “Coley´s toxin”, it furthermore acts directly on 
the tumor neovasculature and induces a hemorrhagic necrosis of the tumor [77].  
An additional subsequent increase in endothelial permeability is induced by VEGF, which is 
supposed to facilitate the invasion of bacteria into the tumor tissue [112]. Due to the 
induction of tumor-vessel hyperpermeability, the bacteria can accumulate inside the 
neoplastic tissue and colonize tumor zones according to their oxygen need. The secretion 
of several pro-inflammatory cytokines and chemokines inside the circulation and tumor 
microenvironment subsequently activates the adaptive immune system. By this adjuvant 
effect of S. Typhimurium, tumor-specific immune responses of T cells are induced [120, 
122]. 
In addition to S. Typhimurium, Pseudomonas aeruginosa is a further opportunistic 
pathogen which is used for the induction of anti-tumor immune responses in tumor-
bearing mice. For example, the subcutaneous application of P. aeruginosa into C57BL/6 
mice induced the rejection of B16-ova tumors [123]. Moreover, Komor et al. [124] showed 
recently that P. aeruginosa successfully colonizes the viable part of solid tumors on BALB/c 
wild-type animals after intravenous injection and induces tumor clearance. Besides that, 
they furthermore observed that the bacteria formed in vivo biofilms inside the tumor 
tissue. Biofilms are defined by Bjarnsholt et al. [125] as “coherent clusters of bacterial cells 
embedded in a biopolymer matrix, which compared to planktonic cells, shows increased 
tolerance to antimicrobials and resists the antimicrobial properties of the host defence”. 
The ability of P. aeruginosa to form biofilms in the host is most likely one ecological 
survival strategy [125]. Due to the biofilm matrix, that mainly consists of 
exopolysaccharides, polypeptides, biomolecules, and extracellular DNA, the bacterium is 
able to overcome immune surveillance and antibiotic treatment in vivo [126, 127]. 
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1.4 Aim of the study 
The knowledge about the host immune system´s impact on tumor development and 
patient survival has strongly increased within the last years. The use of engineered T cells 
and innate immune cells for cancer immunotherapies are new approaches, which directly 
influence the host´s immune system. They are able to convert cell functions within the 
tumor microenvironment from tumor-promoting into tumor-suppressing. One strategy to 
trigger the re-establishment of a pro-inflammatory tumor microenvironment is the 
application of bacteria. For example the injection of S. Typhimurium or Escherichia coli 
induced the rejection of tumors by the activation of CTLs in mice [111, 128]. In the present 
study, the bacterium Pseudomonas aeruginosa was used in a recently described murine 
solid tumor model [129]. The first aim was to confirm that the final anti-tumor effect 
induced by the bacterium is based on the activation of CTLs, and whether this quality is 
tumor specific. 
Tumor cells are able to downregulate or alter their antigen expression pattern. Thereby 
they can evade the antigen-guided responses of immunotherapy. Therefore, further cells 
of the tumor microenvironment should be analyzed for their therapeutic anti-tumor 
features. Neutrophils represent a significant portion of the tumor-infiltrating immune cells 
in murine models as well as in human cancers [130]. Neutrophil numbers are already used 
as prognostic markers for the clinical outcome. For patients suffering from melanoma, 
glioma, or lung-carcinoma, increased numbers of neutrophils are interpreted as negative 
indicators. In contrast, increased numbers of neutrophils stand for a good prognosis for 
gastric carcinoma patients [131-134]. Thus, the use of neutrophils as prognostic markers 
for tumor progression is very much dependent on the tumor type, the applied 
methodology, and the phenotype of the tumor-associated neutrophils [27, 51]. A new 
concept of cancer immunotherapy is therefore to convert pro-tumor N2 neutrophils back 
into tumor-suppressing N1 neutrophils [135, 136]. Using our murine solid tumor model for 
C57BL/6-WT and -IFN-β knock-out mice, the dependency of TANs´ phenotypes on the pro-
inflammatory cytokine IFN-β was recently demonstrated [75]. Since the application of 
P. aeruginosa was supposed to activate the innate and adaptive immune system of tumor-
bearing BALB/c wild-type mice [124], the present study aimed (i) to characterize 
functional phenotypes of TANs in colonized tumor tissues of BALB/c WT mice, (ii) to 
compare the functional specializations of TANs from distinct tumor microenvironments, 
and (iii) to identify pro- or anti-inflammatory triggers influencing such TAN phenotypes in 
vivo. By that, further application possibilities for bacteria-mediated tumor therapy may be 
identified. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Animals 
All experiments were performed with 7 - 12 week old female mice under the approval of 
LAVES (Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit), 
Permission 33.9-42502-04-12/0173. BALB/c WT mice were purchased from Janvier 
(France). BALB/c -Rag1 knock-out and -IFN-β+/∆β-luc transgenic mice were bread in the 
animal facility of the HZI. All mice were kept under elaborate hygiene and specific 
pathogen free conditions with a light-dark cycle of 12 h. 
 
2.1.2 Tumor cell lines and preparation 
CT26 murine colon carcinoma cells (ATCC CRL-2638) or F1A11 murine fibrosarcoma cells 
(kindly provided by Dr. Pablo Becker, HZI, Braunschweig) were cultivated in Iscove’s 
modified Dulbecco’s medium (IMDM) (Invitrogen, USA) supplemented with 10 % (v/v) 
heat-inactivated fetal calf serum (FCS), 250 µmol/l β-mercaptoethanol, and 1 % (v/v) 
penicillin/streptomycin at 37°C and 5 % CO2 in a humidified atmosphere. The inoculum for 
subcutaneous (s.c.) injection into the mice was prepared using the following protocol: 
cancer cells were first shortly washed with Trypsin/Ethylenediaminetetraacetic acid 
(EDTA) to remove dead cells on the cell layer, before they were incubated for 5 min at 
37°C in Trypsin/EDTA till the cancer cells detached from the culture flask. 15 ml pre-
warmed IMDM was added to stop the reaction and carefully dissolve cancer cell clots. The 
cell suspension was transferred into a 50 ml falcon and filled up to 40 ml with IMDM, and 
centrifuged (5 min, 120 rmp, RT). The cell pellet was washed in 25 ml pyrogen-free 
phosphate-buffered saline (PBS) (Biochrom, Germany) by centrifugation (5 min, 120 rmp, 
RT), before the cancer cells were resolved in PBS and a 10 µl aliquot was used to 
determine the cell number. Therefore the cells were 1:10 diluted in 0.5 % w/v Trypan 
blue/PBS and counted within a Neubauer chamber using a light microscope. The inoculum 
was adjusted to get 5x105 cancer cells per 100 µl PBS per mouse. 
 
 
Materials and Methods 27 
 
2.1.3 Bacterial culture and preparation 
The Pseudomonas aeruginosa wild-type strain PA14 (UCBPP-PA14, kindly provided by 
Prof. Dr. Susanne Häußler) is a burn wound isolate and was used for infections exclusively. 
Bacteria were cultivated out from frozen samples kept at -80°C on LB-plates 
supplemented with 100 µg/ml ampicillin for 1 day at 37°C, before they were prepared for 
injection. To this end, several colonies were dissolved in 1 ml pyrogen-free PBS and spun 
down (5 min, 6.000 rmp, RT). The pellet was washed again in 1 ml PBS (5 min, 6000 rmp, 
RT) and afterwards resolved in 1 ml PBS. A 1:10 dilution in PBS was used to determine the 
OD600 of the cell solution within the linear range (OD600 0.1 – 1) of the photometer. The 
inoculum was adjusted to OD600 of 0.065 which was equivalent to approximately 5x10
6 
bacteria per 100 µl injected per mouse. Alternative OD600-values of 0.0009, 0.009, or 0.525 
were justified to obtain 5x104, 5x105, or 5x107 bacteria. The exact infection dose was 
always determined by subsequent plating of the final inoculum. 
 
2.1.4 Antibodies 
Table 2: Utilized antibodies for flow cytometric and histological analyses 
 
Specificity Clone Fluorochrome Dilution Company 
CD3 145-2C11 FITC 1:200 eBioscience 
CD4 RM4-5 APC 1:200 eBioscience 
CD8 53-6.7 PE 1:400 eBioscience 
CD19 1D3 APC-Cy7 1:150 BD 
CD45 30-F11 APC-Cy7 1:400 BioLegend 
CD11c N418 PE-Cy7 1:200 eBioscience 
CD11b M1/70 APC 1:500 eBioscience 
CD11b M1/70 PE-Cy5 1:300 eBioscience 
Ly6G 1A8 PE-Cy7 1:500 BioLegend 
Icam YN1/1.7 FITC 1:200 eBioscience 
Fas 15A7 PE 1:200 eBioscience 
CD62L MEL-14 Biotin 1:200 eBioscience 
Ki-67 (rabbit) SP6 x 1:800 NeoMarkers 
TNF-α MP6-XT22 FITC 1:100 eBioscience 
Active caspase 3 C92-605 PE 1:10 BD 
MPO (rabbit) polyclonal x 1:200 Medac 
P. aeruginosa polyclonal x 1:150 BIOTREND 
AA-Lectin x Biotin 1:200 Vector Laboratories 
Streptavidin x APC 1:400 BD 
Streptavidin x PerCP-Cy5.5 1:1500 eBioscience 
Goat-anti-rabbit polyclonal Alexa488 1:200 Invitrogen 
Goat-anti-rabbit TR-060-BN Biotin  Thermo Fisher 
Rabbit-anti-pimonidazole PAb2627AP x 1:1600 HypoxyprobeTM-1 
Succinimidyl ester x Alexa350 1:1000 Thermo Fisher 
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2.2 Methods 
2.2.1 Tumor model 
Mice were immobilized, their abdomen was shaved, and 100 µl with 5x105 CT26 cells 
solved in pyrogen-free PBS were injected s.c.. Tumors established for 10 days to have an 
optimal size of 100-150 mm³. Next, the mice were intravenously (i.v.) injected with 5x106 
bacteria or 1 µg recombinant TNF-α in 100 µl PBS, or solely pyrogen-free PBS as control. 
Tumor development was monitored by size measurement with a caliper and calculation of 
the tumor volume by the formula: V = 4/3 · π (h · w2) / 8, h = tumor height and w = tumor 
width. At defined time points after bacterial infection, PBS- or TNF-α treatment, the mice 
were sacrificed and organs, as well as tumors were analyzed by the several methods. 
Mice, which had been infected with P. aeruginosa before they cleared the tumors, were 
treated twice with 10 mg/kg Ciprofloxacin (CiproHEXAL, Hexal AG, Germany) 1 day before 
they were re-challenged with cancer cells. 
 
2.2.2 Adoptive T cell transfers 
Spleens of BALB/c WT mice were flushed with 5 ml IMDM on ice, filtered through a 50 µm 
filter (Cell Trics, Partec), and spun down (8 min, 1200 rpm, 4°C). The erythrocytes in the 
cell pellets were lysed in ammonium-chloride-potassium (ACK) buffer (8.29 g NH4Cl, 1.0 g 
KHCO3, 200 µl 0.5 M EDTA per liter H2O, pH 7.3, sterile) for 2 min, before the reaction was 
stopped by 10 ml IMDM, and the solution was centrifuged (8 min, 1200 rpm, 4°C); this 
procedure was repeated once. The isolated splenocyte pellets were used to isolate total-, 
CD4+-, or CD8+ T cells by use of negative isolation kids (Dynabeads Untouched Mouse 
T cells, or CD4 / CD8 T Cells (Invitrogen, USA)). For adoptive transfer, 2x107-3.5x107 T cells 
were injected i.v.. To determine the exact number of transferred cells, an aliquot was 
diluted 1:1000 in PBS and Trypan blue, and counted in a Neubauer chamber using a light 
microscope. The purity was controlled by flow cytometry and incubation of the cells with 
first an anti-mouse CD16/CD32 antibody to block Fc receptors on the cells surface to avoid 
unspecific binding of the afterwards applied antibodies against (i) CD3, CD4, CD8 to detect 
the respective T cell subset, (ii) CD19 to exclude B cells, and (iii) CD11b as well as CD11c to 
exclude myeloid cells. 
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2.2.3 Flow cytometry of tumor-infiltrated neutrophils  
Tumor tissues were digested (45 min, 37°C, moved) using a dispase 
(0.2 mg/ml)/collagenase A (0.2 mg/ml)/DNase (100 mg/ml) solution. The cell 
homogenates were meshed through 50 µm filters (Sysmex Partec GmbH, Germany), spun 
down (5 min, 1000 rmp, 4°C), and erythrocytes were removed by 2 min ACK-lysis. The cell 
suspension was washed in 4 ml fluorescence-activated cell sorting (FACS)-Buffer (PBS, 2 % 
FCS, 0.5 M EDTA) (5 min, 1000 rmp, 4°C), and single cell suspensions were prepared. These 
were each firstly incubated in 200 µl brefeldin-A (2 h, 37°C) to block the golgi-apparatus 
and, if an intracellular staining was applied, additionally stained with an Alexa Fluor 350 
succinimidyl ester to visualize dead cells. Afterwards, all samples were firstly labeled with 
an anti-mouse CD16/CD32 antibody to block Fc receptors and secondly with the 
appropriate antibodies against CD45, CD11b, Ly6G, Icam, Fas, TNF-α, active caspase 3, and 
CD62L. For intracellular staining, samples were next fixed and permeabilized using the 
Cytofix-Cytoperm buffer (BD Bioscience, USA), before antibodies for intracellular targets 
were applied. Samples for extracellular antibody detection were mixed with Dapi directly 
before measurement to discriminate live and dead cells. Flow cytometry was performed 
using the LSRII system (BD Bioscience, USA) and the corresponding data were analyzed 
using the BD FACSDiva software (BD Bioscience, USA). 
 
2.2.4 Luminex analyses of serum and tumor lysate 
Heartblood was taken with a 26 G needle, filled into serum tubes (Sarstedt, Germany), 
incubated for 10 min at RT to enable agglutination, and centrifuged (5 min, 10,000 rmp, 
RT). The serum was 1:2 diluted in Sample Diluent buffer (BioRad laboratories Inc., USA) for 
analyses. Tumors were cut off from the mouse skin, incubated in lysis buffer (9.9 ml 
Bioplex Cell Lysis Buffer, 40 µl Bioplex Cell Lysis Buffer Factor 1 (250x), 20 µl Bioplex Cell 
Lysis Buffer Factor 2 (500x) (all from BioRad laboratories Inc., USA), 40 µl 500 mM 
phenylmethylsulfonyl fluoride (Sigma-Aldrich, USA)) and dissected into homogeneous 
1 mm pieces on ice. Afterwards, the samples were vortexed, incubated for 20 min at  
-80°C, thawed for 20 min at RT, placed for 10 min into an ultrasonic bath at 4°C, stored 
again for at least 20 min at -80°C, and also thawed again for 20 min at RT. After vortexing, 
the samples were spun down (20 min, 13,000 rmp, 4°C), and the supernatant was taken 
for determination of the protein concentration by the use of PierceTM BCA protein assay 
kit (Thermo Fisher Scientific Inc., USA). Tumor lysates were diluted to 1 mg/ml with 
Sample Diluent buffer (BioRad laboratories Inc., USA) for the subsequent analyses. 
Cytokine concentrations in serum and tumor lysates were quantified by the Luminex-
based multiplex technique according to the manufacturer’s instructions (BioRad, USA).  
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Standard curves and concentrations were calculated with Bio-Plex Manager 6.1 software. 
Analyses and evaluations were kindly performed by Kerstin Daemen and Prof. Dr. 
Christine Falk at the Institute of Transplantation Immunology, Hannover Medical School. 
 
2.2.5 Histology 
2.2.5.1 Light microscopy of paraffin sections 
Tumors were cut out and fixed for 24 - 48 h in 4 % (v/v) formalin, before they were 
embedded in paraffin. Consecutive 3 µm sections were cut and stained with antibodies 
against Ki67, MPO, pimonidazole, and P. aeruginosa according to standardized protocols. 
Streptavidin conjugated with horseradish peroxidase was used as a secondary reagent 
(Thermo Fisher Scientific, USA) and incubated with 3,3´-diaminobenzidine (DAB) (Zytomed 
Systems, Germany) as peroxidase-compatible chromogen. Hematoxylin was used as 
counterstain. For the immunohistochemical detection of hypoxia inside tumors, 1.5 mg 
solid pimonidazole HCl (HypoxyprobeTM-1, USA) were solved in 100 µl saline per mouse 
and applied i.v. 1 h prior to sacrifice and sample preparation. Sections were additionally 
stained with hematoxylin and eosin to visualize tumor tissue structures including blood 
vessels and infiltrated cells. Preparations of samples were kindly performed by Anna 
Rinkel, Rebecka Wünsche, and Dr. Marina Pils at the mouse-pathology platform of the HZI. 
 
2.2.5.2 Confocal laser scanning microscopy of cryosections 
Tumors were cut out, embedded in Tissue Tek O.C.T (Sakura, USA) and snap frozen for 
10 min in liquid nitrogen before they were put to -21 C or stored at -80°C. Sections of 
10 µm were cut using a microtome-cryostat (HYRAX C50 Zeiss, Germany) and dried 
overnight (RT). Sections were rehydrated in PBS (15 min, RT), labeled with an anti-mouse 
CD16/CD32 antibody to block Fc receptors on the cells surface to avoid unspecific binding, 
and stained with the appropriate antibodies against P. aeruginosa, Aleuria Aurantia (AA)-
Lectin, CD11b, and Gr-1. Afterwards the sections were dried for 15 min under the 
chemical hood and mounted with NeoMount and a coverslip. Analyses were performed at 
a laser scanning confocal microscope (LSM 5 META, Zeiss, Germany) and the images were 
processed by the LSM 5 Image Browser software (Zeiss, Germany).  
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2.2.5.3 Electron microscopy of ultra-thin resin sections 
Tumors were cut out and fixed at least for 24 h in a solution of 5 % formaldehyde and 2 % 
glutaraldehyde in cacodylate buffer (0.1 M cacodylate, 0.01 M CaCl2, 0.01 M MgCl2, 
0.09 M sucrose, pH 6.9). Out of one tumor, several cubes of 4 mm diameter were 
prepared and osmificated for 1 h in 1 % aqueous osmium tetroxide, before they were 
washed for 1 h in cacodylate buffer. Several steps of dehydration with graded series of 
acetone (10 %, 30 %, 50 %, 70 %, 90 %, 100 %) were performed for 30 min each, out of 
which the 70 % step was done overnight with 2 % uranyl acetate. The cubes were than 
infiltrated with an epoxy resin according to Spurr´s formula. A diamond knife was used to 
cut ultrathin sections of the cubes. These were picked up with formvar-coated grids, 
counterstained with uranyl acetate and lead citrate, and analysed by a TEM910 
transmission electron microscope (Zeiss, Germany) at an acceleration voltage of 80 kV. 
The depicted images were taken at calibrated magnifications and processed with an ITEM-
software (Olympus Soft Imaging Solutions, Germany). Preparations and evaluations of the 
samples were kindly performed by Ina Schleicher and Prof. Dr. Manfred Rohde at the 
electron microscopy platform of the HZI. 
 
2.2.6 Detection of luciferase activity in vivo 
Tumor-bearing IFN-β+/∆β-luc mice were treated with the respective inoculum, i.v. injected 
with 150 mg/kg D-luciferin (Perkin Elmer, USA) prior to each imaging, anesthetized using 
2 % Isofluran (Abbott, USA), and monitored with an IVIS 200 imaging system (Xenogen, 
USA) [137]. The resulting photon flux, reflecting the enzymatic activity of luciferase which 
corresponds to the amount of expressed IFN-β, was quantified using the Live Imaging 3.0 
software (Perkin Elmer, USA). 
 
2.2.7 Statistical analyses 
All statistical analyses were performed on ex vivo data of small groups with less than 
10 mice. Therefore the data were always presented as median and the error bars 
represented the range of the median. Significances were calculated by the Mann-Whitney 
Test for comparison of two groups using the software GraphPad Prism 5 (GraphPad 
Software Inc., USA). 
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3 Results 
In the present study the well-established tumor colonization properties of Pseudomonas. 
aeruginosa should be used to better understand the biology of bacteria-mediated tumor 
therapy. Especially parameters of the anti-tumor response of the innate as well as the 
adaptive immune system should be studied. For this purpose, first optimal parameters for 
the colonization of tumors by P. aeruginosa had to be established. 
 
3.1 Optimal parameters for tumor colonization 
To be able to reliably receive a maximal colonization of infected tumors, some parameters 
of the model system needed to be calibrated. First, the influence of the tumor size on a 
sufficient colonization with P. aeruginosa was investigated. Syngeneic CT26 tumor cells 
were s.c. injected on different days into the respective hosts to receive a broad spectrum 
of tumor sizes at the day of infection, such that the same bacterial inoculum could be used 
for all tumor-bearing mice. 
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Figure 10: Efficiency of tumor colonization is tumor size-dependent 
To get various tumor sizes, cancer cells were injected on several days. Tumors of 7-23 mm³ were 2 to 5 days 
old, 24-43 mm³ tumors were 7 days old, 47-237 mm³ tumors developed for 9 days, and 146-410 mm³ 
tumors developed for 13 days. Mice were infected with 2.33 or 4.4x10
6
P. aeruginosa* and tumors were 
analyzed 2 days later for bacterial colonization by plating. Bars represent individual mice, *combined from 
two experiments, and depicted in 100 mm³-stages. Data published in Pawar V., Komor U., Kasnitz N. et al. 
[138]. 
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As shown in (Figure 10, p.32), tumors with a smaller size than approximately 100 mm³ 
carried the risk of not being colonized by bacteria whereas tumors in the range between 
100 to 400 mm³ were all well colonized. Normally, after around 10 days of development 
tumors reached a size of 100-150 mm³. At that size they were obviously sufficiently 
vascularized to guarantee a robust bacterial colonization. Therefore, the optimal time 
point to infect tumor-bearing BALB/c WT mice was 10 days after CT26 cell inoculation with 
5x105 cells. 
Besides the tumor volume, the infection dose could also be very important for stable 
tumor colonization. The inoculum represents furthermore the most critical parameter for 
the health of the mice. It should therefore be as low as possible to limit the burden for the 
animals. On the other hand, it should be high enough to ensure a robust colonization of 
the tumor tissue. Based on the above established optimal tumor volume, different 
infection doses of P. aeruginosa PA14 were tested (Figure 11). 
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Figure 11: Efficiency of tumor colonization is infection dose-dependent 
When tumors had optimal sizes of about 100-150 mm³, mice were i.v. infected with 4.7x10
4
 (10
4
), 6.3x10
5
 
(10
5
), 4.0x10
6
 (10
6
), and 3.8x10
7
 (10
7
) P. aeruginosa PA14 in 100 µl PBS. Tumors were plated 2 d p.i. to 
analyze bacterial colonization. Bars represent individual mice of one experiment. Data published in Pawar V., 
Komor U., Kasnitz N. et al. [138]. 
An injection dose of less than 5x106 P. aeruginosa per tumor-bearing WT mouse did not 
result in a sufficient colonization (Figure 11): with 5x104 injected bacteria the tumors were 
not colonized at all, and when 5x105 bacteria were applied only some tumors were 
colonized, but to a lower degree. In contrast, with an injection of 5x107 P. aeruginosa per 
mouse, all tumors were in fact highly colonized. However, the health burden for the mice 
was too high. They showed rough fur and agglutinated eyes. 
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A systemic infection with 5x106 P. aeruginosa PA14 appeared to be optimal. All tumors 
were colonized to a high degree. The health burden was acceptable thus allowing 
observations over several days. 
 
3.2 Tumor development after bacterial infection 
Within the first day after intravenous administration of the bacteria, the visible phenotype 
of the transplanted subcutaneous tumors changed. The clinically detectable, well 
vascularized, and reddish-looking tumors turned into a red-dark to black color (Figure 12). 
The mice behaved normal and did not show any kind of health burden. This tumor 
phenotype was independent from the genotype of the mice used during the studies and 
appeared always within 1 day post i.v. infection. 
                    
Figure 12: Development of necrotic tumors after infection 
Tumor-bearing mice were i.v. infected with 6.3x10
6
 P.aeruginosa PA14 in 100 µl PBS after 10 days of tumor 
growth. After the first 24 h after infection, the visible phenotype of the s.c. tumor appeared to be dark. The 
depicted tumor illustrates a general effect observed in all infection experiments. 
To see the long term consequences of tumor colonization on tumor growth, tumor-
bearing BALB/c WT mice were infected i.v. with P. aeruginosa and the ongoing 
development of tumor size was followed. Tumors started to decrease in size already 
within the first 24 h after infection (Figure 13, p.35). This trend was significant with p<0.05 
on day 3 p.i. and with p<0.01 from day 5 p.i. onwards. On day 13 p.i. all tumors were 
rejected completely and the mice stayed tumor free without any further treatment.  
1d 
Results 35 
 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38
0
40
80
120
160
*
**
Days post infection
Tu
m
o
r 
v
o
lu
m
e
 
(m
m
³)
 
Figure 13: Tumor rejection after intravenous infection of WT mice 
Tumor-bearing BALB/c WT mice were i.v. infected with 3.6x10
6
 P. aeruginosa PA14 when tumors had 
reached an optimal size of about 100-150 mm³. Data are represented as median and range from n=6 of one 
experiment. For statistical analyses the Mann-Whitney test, one-tailed, *p<0.05, ** p<0.01 were used to 
compare respective tumor sizes with the tumor size on the day of infection (d0). 
To investigate whether bacterial induced rejection of the CT26 tumors was due to a 
reaction of the adaptive immune system, mice that had cleared the tumor were re-
challenged with CT26 colon carcinoma cells after 43 days of tumor clearance. Two 
treatments with 10 mg/kg CiproHEXAL (Hexal AG, Germany) were made 1 day before 
tumor setting to exclude any residual bacterial influence on tumor development. For this 
re-challenge, the CT26 cells were injected into the right side of the abdomen to exclude 
any inflammatory local influences, since the rejected CT26 tumors had been implanted on 
the backs of the animals. At the same time the mice received a second cancer cell line, 
F1A11 fibrosarcoma cells, injected s.c. into the left side of the abdomen as specificity 
control. Because the F1A11 cancer cells are unrelated to CT26 cells and were applied for 
the first time, the immune system of the host, if involved in the rejection process, should 
not be able to counteract F1A11 development, while it should strongly react against the 
original CT26. Both tumor cell lines started to develop and became palpable within the 
first 5 days after injection (Figure 14, p.36). Whereas the CT26 tumors eventually started 
to decrease in size and were finally completely rejected, the F1A11 tumors grew 
continually. Starting on day 5 p.t., the two distinct tumors on the abdomen of individual 
mice showed significant size differences with p<0.01 from day 7 p.t. onwards. Importantly, 
only the CT26 cancer cells were rejected for which the mice should have developed an 
immune memory. Thus, the reaction was specific.  
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These two criteria, memory and specificity, are characteristic for the adaptive immune 
system and indicated that a specific immune reaction was involved in the process of 
tumor rejection. 
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Figure 14: Tumor development after first- or repetitive cancer cell challenge in WT mice 
Tumor-free BALB/c WT mice were s.c. treated with two different cancer cell lines at a time. They received 
CT26 colon carcinoma cells for a second time (2nd) and F1A11 fibrosarcoma cells for the first time (1st). Both 
were injected into the abdomen, since the previous CT26 tumor was implanted into the back. Data are 
represented as median and range from n=6 of one experiment. For statistical analyses the Mann-Whitney 
test, one-tailed, *p<0.05, ** p<0.01 was used to compare tumor sizes of CT26 and F1A11 tumors at the 
same time point. 
To confirm the importance of the adaptive immune system for tumor rejection in our 
infection model, BALB/c Rag1-/- mice which lack the adaptive arm of the immune system 
were employed. The progress of CT26 tumor development was compared between 
infected BALB/c WT and Rag1-/- mice (Figure 15, p.37). Already before infection, tumors on 
Rag1-/- mice grew faster than on WT mice. The difference in tumor size between the two 
mice genotypes diverged from day 7 of tumor growth (reflected as day -3 in Figure 15, 
p.37) onwards. This indicates that already under undisturbed conditions the adaptive 
immune system exerts a certain cancer control. As expected, after infection with  
P.  aeruginosa only tumors on WT mice started to shrink, whereas the same tumor cell line 
continued to grow on Rag1-/- animals (Figure 13, p.35). This confirms that tumor rejection 
of bacterial infection is elicited by a tumor specific immune reaction.  
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Figure 15: Distinct tumor development in syngeneic mice 
Tumor development was investigated in BALB/c WT and Rag1
-/- 
mice, infected on day 10 with 6.2x10
6
 
P. aeruginosa PA14. Data are represented as median and range from n=12 of one experiment. For statistical 
analyses the Mann Whitney test, one-tailed, *p<0.05, ** p<0.01, *** p<0.001 were used to compare tumor 
sizes on WT and Rag1
-/-
 on the same day. 
 
3.3 Contribution of T-lymphocytes on tumor development and therapy 
The tumor-suppressive impact of especially effector T cells is well established. Therefore, 
Rag1-/- mice were reconstituted with different T cells and the subsequent tumor 
development was compared to unmodified Rag1-/- mice. No additional infection was 
applied to the mice. Splenic total T cells (CD4+ and CD8+) from differentially treated or 
untreated BALB/c WT animals were used for the experiment. These included T cells of 
naïve BALB/c mice, T cells of WT mice which were each bearing a 12 day old tumor, and 
T cells from WT mice which have been infected with P. aeruginosa after 10 days of tumor 
growth and were at that time tumor free since 40 days. The growth of tumors on naïve 
Rag1-/- mice and on Rag1-/- mice adoptively modified with naïve T cells was similar (Figure 
16, p.38). In contrast, the transfer of T cells from tumor-bearing mice retarded the growth 
of tumors from day 9 p.t. onwards. However, only the transfer of T cells isolated from 
mice, which have been able to clear tumors after P. aeruginosa infection enabled the 
rejection of tumors in uninfected Rag1 mice. From day 11 onwards, the median tumor size 
of that group was significantly smaller than that of naïve Rag1-/-animals. 
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Figure 16: Total T cells-priming-dependent tumor development after adoptive transfer 
Tumor development in Rag1
-/-
 mice and reconstituted Rag1 mice was compared. For the adoptive transfer, 
mice received differentially stimulated splenic CD4
+
+CD8
+ 
T cells of BALB/c WT mice: (i) 2x10
7
 naïve T cells 
(Tc naïve), (ii) 3x10
7
 T cells of tumor-bearing mice (Tc bearing) with tumor growth since 12 days, and (iii) 
3x10
7
 T cells from previously infected mice which had cleared tumors since 40 days (Tc cleared). Data are 
represented as median and range from n=3-4 of one experiment. For statistical analyses the Mann-Whitney 
test, one-tailed, *p<0.05 was used to compare tumor sizes of Rag1
-/-
 and modified Rag1 mice (i-iii) on the 
same time point. Statistical data represent comparison for (iii). Data published in Stern C., Kasnitz N. et al. 
[111]. 
To test if isolated splenic CD4+ or CD8+ T cells are sufficient to decrease tumor growth or 
even to reject tumors completely, the individual cells were independently isolated and 
transferred into Rag1-/- animals together with CT26 tumor cells. Again, the tumors on 
unmodified Rag1-/- animals and on those Rag1-/- mice transferred with naïve total T cells 
from BALB/c mice grew very similar (Figure 17, p.39). A weak retardation in tumor growth 
did occur after transfer of CD4+ T cells from tumor-bearing mice. This was significantly 
different with p<0.05 to the tumor growth on Rag1 animals that received naïve T cells 
from day 11 onwards (Figure 18B, p.40). The transfer of equal numbers of CD8+ T cells of 
tumor-bearing mice exhibited significantly stronger growth retardation. Even though such 
T cells were not sufficient to suppress tumor development, they did show a stronger 
tumor-suppressive effect than the CD4+ T cells of tumor-bearing WT mice with p<0.01 
(Figure 18B, p.40). However, by applying a mixture of both kinds of such T cells at the 
same time, tumors were already significantly smaller on day 6 p.t. compared to Rag1 mice 
treated with naïve total T cells. Most of these mice were even able to reject CT26 tumors 
completely. Only one out of four tumors started to re-grow between day 11 and 14 after 
cancer cell injection. This explains the increasing range of the median in Figure 18A+B, 
p.40.  
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Figure 17: CD4
+
- and CD8
+
 T cells-priming influences tumor development after adoptive transfer 
Tumor development in naïve and reconstituted Rag1
-/-
 mice stimulated with splenic CD4
+
, CD8
+
, or total (Tc) 
T cells out of BALB/c WT mice: (i) 3.5x10
7
 naïve total T cells (Tc naïve), (ii) 3x10
7
 T cells (CD4
+
, CD8
+
, Tc 
bearing) of tumor-bearing mice with tumor growth since 12 days, (iii) 3x10
7
 T cells from previously infected 
mice which had cleared tumors since 4 month (CD4
+
, CD8
+
, Tc cleared). Data are represented as median and 
range from n=4-7 of one experiment and are separated per treatment in Figure 18 , p.40 and Figure 19, p.41.  
The strongest anti-tumor reaction of all eight analyzed groups in Figure 17 showed Rag1-/- 
mice, which had received T cells from mice that had been infected and consequently 
cleared the tumors. After injection of isolated CD4+ T cells from such mice, the tumor 
development was admittedly decreased with a significance of p<0.01 from day 8 onwards 
(Figure 19B, p.41). But this group of seven mice reacted heterogeneous, which was 
reflected by the increased range of the tumor size median. Three mice showed tumor 
rejection, whereas tumors continued to grow on four mice. The transfer of equivalent 
CD8+ T cells showed a more prominent effect. From day 11 of tumor growth onwards, 
tumors of such Rag1 mice were significantly smaller with p<0.01 than tumors on mice 
treated with naïve total T cells. A complete tumor rejection did occur in three of five mice, 
therefore in Figure 19B (p.41) only the range of the median at day 18 and 21 p.t. is shown. 
An even stronger trend was observed by the injection of total T cells from mice that had 
cleared the tumors. In that case, tumors were already significantly smaller with p<0.01 
from day 8 after transfer of tumor and T cells onwards, and all the mice were tumor free 
from day 18 on. The impact of purified CD8+ T cells and total T cells from tumor-immune 
mice on the development of new CT26 tumors was similar. No significant difference 
between the median tumor sizes of the respective groups was detected (Figure 19, p.41). 
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Figure 18: T cells out of tumor-bearing mice retard tumor growth after adoptive transfer 
Figure 17, p.39 in detail. A: tumor growth on reconstituted Rag1 mice which received splenic CD4
+
, CD8
+
,or 
total (Tc) T cells out of BALB/c WT mice: (i) 3.5x10
7
 naïve total T cells (Tc naïve) or (ii) 3x10
7
 T cells of tumor-
bearing mice (CD4
+
, CD8
+
, Tc bearing) with tumor growth since 12 days. B: Comparison of tumor growth. 
Data are represented as median and range from n=4-7 of one experiment. The Mann-Whitney test, one-
tailed was used to compare tumor sizes at the same time point: *p<0.05, **p<0.01 to compare Tc naïve with 
CD4
+
/CD8
+
/Tc bearing. #p<0.05, ##p<0.01 to compare CD4
+
/CD8
+
 Tc bearing with total T cells bearing. 
Groups were analyzed in 3 independent experiments. 
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Figure 19: CD8
+
 T cells out of treated tumor-free mice reject tumors after adoptive transfer 
Figure 17, p.39 in detail. A: tumor growth on reconstituted Rag1 mice which received splenic CD4
+
, CD8
+
,or 
total (Tc) T cells out of BALB/c WT mice: (i) 3.5x10
7
 naïve total T cells (Tc naïve) or (ii) 3x10
7
 T cells from 
previously infected mice which had cleared tumors since 4 month (CD4
+
, CD8
+
, Tc cleared). B: Comparison of 
tumor growth. Data are represented as median and range from n=4-7 of one experiment. The Mann-
Whitney test, one tailed was used to compare tumor sizes at the same time point. **p<0.01 to compare Tc 
naïve with CD4
+
/CD8
+
/Tc cleared. ##p<0.01 to compare CD4
+
/CD8
+
 Tc cleared with total T cells cleared. 
Groups were analyzed in 2 independent experiments. 
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3.4 Tumor-associated neutrophils and -cytokines 
When tumor-bearing BALB/c or Rag1-/-mice were infected with P. aeruginosa, CT26 
tumors changed their macroscopic appearance from reddish to a dark color within 24 h 
p.i. (Figure 12, p.34). In the following, such tumors started to shrink in WT mice and were 
cleared within 13 days (Figure 13, p35). To investigate how the tumor microenvironment 
of CT26 solid tumors looks like after infection and onset of tumor-suppressive processes, 
immune histology was deployed. Consecutive sections of tumors were stained with 
different antibodies or reagents.  
First, the formation of different tumor zones 3 days p.i. was detected by hematoxylin-and-
eosin (H&E) staining (Figure 20A, p.43): the outer layer of the tumor was surrounded by 
the skin (S) of the mouse with hairs and sebaceous glands, subcutaneous tissue, and 
musculature (M) close to the connective area of the abdomen. The tumor underneath 
started with a circular zone of viable tumor cells (V). A second ring of viable, highly 
nucleated cells (G) was formed between the outer tumor zone and the inner necrotic 
tumor area (N). The classification of tumor infiltrated cells as tumor-associated 
neutrophilic granulocytes (G) was possible by using a higher magnification of the H&E 
image and thereby identifying the typical neutrophil nuclear shape (magnification image is 
depicted in Pawar V., Komor U., Kasnitz N. et al.[138]). This visual analysis serves as the 
gold standard for a correct identification of neutrophils [35]. In addition, anti-
myeloperoxidase staining was performed which specifically revealed such granulocytes 
(Figure 20B, p.43). The purple circle in Figure 20A was identical to the brown circle in 
Figure 20B.  
Plating experiments had demonstrated a strong colonization of tumors by P. aeruginosa 
(Figure 11, p.33). Hence, the side of bacterial localization was highlighted by an anti-
P. aeruginosa staining (Figure 20C, p.43). These microscopical analyses revealed several 
small areas of bacterial colonization. They were located between the viable and the 
necrotic tumor zones, and in close proximity or even co-localized with neutrophilic 
granulocytes.  
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Figure 20: TANs reside close to the necrotic 
area and P. aeruginosa inside tumors. 
The CT26 tumor on a BALB/c mouse was 
collected 3 days p.i. with 1x10
6
 P. aeruginosa 
and several consecutive sections were 
prepared. Sections were stained with: A: 
Hematoxylin-and-eosin to highlight viable (V) 
and necrotic (N) regions within the tumor. 
Around the tumor were the mouse skin (S) and 
musculature (M). The dark purple and circular 
area representing infiltrated cells with intact 
nuclei was further characterized in B: Staining 
with diaminobenzidine-myeloperioxidase to 
highlight neutrophilic granulocytes (G). C: 
P. aeruginosa highlighted by a 
diaminobenzidine-P. aeruginosa antibody (P). 
For the analyses, pictures of the sections were 
made transparently and put on top of each 
other to label exactly the same areas in all 
images and to demonstrate relative proximity. 
Image A is published in in Pawar V., Komor U., 
Kasnitz N. et al. [138]. 
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Since neutrophils are mobilized to the tumor by cytokines and chemokines, which also 
induce their polarization, luminex analyses were performed on tumor lysates. Among the 
cytokines detected were molecules that influence the migration of neutrophils, and 
support their functional polarization, but also molecules which act on endothelial cells and 
might therefore influence the permeability of the tumor neovasculatur and neutrophil 
infiltration (Figure 21A+B).  
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Figure 21: Cytokines in the tumor microenvironment of infected WT mice 
Luminex analyses were performed on tumor lysates 1 d (A) and 3 d p.i. (B) of WT mice with 5x10
6
 
P. aeruginosa. Black bars represent neutrophil chemoattractants, whereas gray bars indicate molecules 
responsible for the activation and polarization of neutrophils. White bars show molecules which act on 
endothelial cells. Arrows on the y-axis indicate an increased concentration of molecules 3 d p.i.. Data are 
represented as median and range from n=2 of one experiment.  
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The chemokines KC / CXCL-1, MIP-2 / CXCL-2, and MCP-1 (monocyte chemoattractant 
protein) / CCL-2 mainly attract neutrophil migration. The concentration of MIP-2 increased 
tremendously between day 1 and day 3 p.i. (Figure 21A+B, p.44). This might indicate an 
essential role of MIP-2 for the permanent attraction of neutrophils into the tumor. The 
chemokines KC and MCP-1 appeared to be less involved in the migration process. The 
cytokines G-CSF, GM-CSF, TNF-α, IL-1β, and IL-12 (p70) were present to low amounts in 
tumors on day 1 p.i. and showed even decreased concentrations on day 3 p.i. whereas the 
concentrations of IL-12 (p40), IL-15, and IL-18 were slightly increased two days later 
(Figure 21A+B, p.44). They all belong to a group of molecules in the tumor 
microenvironment that can influence the general polarization of neutrophils and induce 
the release of cytokines and chemokines by the cells. Furthermore, they can inhibit 
neutrophil apoptosis and thereby prolong the cells survival. The concentrations of VEGF 
and PDGF-bb (platelet-derived growth factor with two B-chains) stayed constant between 
day 1 p.i. and day 3 p.i.. Since VEGF was detected in high concentrations, it might have 
played a more important role for the infiltration of cells and bacteria into the tumor.  
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Figure 22:Neutrophil chemoattractants in the circulation of infected WT mice 
Luminex analyses were performed on heart blood 2 h, 24 h, and 72 h p.i. of WT mice with 5x10
6
 
P. aeruginosa. The illustrated molecules can influence the migration of neutrophils. Data are represented as 
median and range from n=2 of one experiment. 
To investigate whether the five analyzed chemoattractants that neutrophils respond to 
are only available inside the tumor or also present in the circulation, blood samples from 
the same mice were also analyzed at different time points to see whether a chemokine 
gradient between the circulation and the tumor tissue existed.  
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All of such neutrophil chemoattracting molecules were available within the circulation of 
the host (Figure 22, p.45), whereas only three of them (KC, MIP-2, and MCP-1) were 
detectable in the corresponding tumor lysates (Figure 21A+B, p.44). The concentration of 
the four chemokines KC / CXCL-1, MCP-1 / CCL-2, MIP-1α / CCL-3, and Rantes / CCL-5 in 
blood increased over time, and reached different final levels with KC > MCP-1 > MIP-1α > 
Rantes. The only chemokine which was already upregulated at 2 h p.i. was MIP-2 / CXCL-2.  
Since chemoattracting gradients should became apparent, the concentrations of such 
molecules in circulation and the tumor lysates were directly compared to discover the 
direction of chemokine gradients decisive for neutrophil migration. The chemokine MIP-2 
was highly present in the circulation at 2 h p.i., but available in prominent concentrations 
only within the tumor microenvironment later on (Figure 23). Thus, it seemed to be 
initially responsible for neutrophil mobilization from the BM into the blood once bacteria 
are applied. While MIP-2 seemed to be responsible for the early extravasation of 
neutrophils into the tumor as a side of infection, alternative chemokines seemed to be 
responsible for that at later time points.  
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Figure 23: Neutrophil chemoattractants in blood and tumor of infected WT mice 
Luminex analyses of neutrophil chemoattractants performed on heartblood (B, gray bars) and tumor lysates 
(T, black bars) of the same mice after 2 h, 24 h, and 72 h p.i. with 5x10
6
 P. aeruginosa. Data are represented 
as median and range from n=2 of one experiment. 
Since neutrophils are also part of uninfected, growing tumors (see also later in Figure 
26A+C, p.50), the concentrations of the same cytokines were also compared in blood and 
tumor lysates of uninfected WT mice. Under these circumstances all cytokines were found 
in blood and tumor lysate, especially at later time points (Figure 24).  
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Therefore they might all be important for the mobilization and chemoattraction of 
neutrophils, their intra- and extravasation, and the development of TAN populations 
under undisturbed conditions of tumor growth.  
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Figure 24: Neutrophil chemoattractants in blood and tumor of uninfected WT mice 
Luminex analyses performed on heartblood (B, gray bars) and tumor lysates (T, black bars) of the same mice 
after 11 d (=2 h), 12 d (=24 h), and 14 d (=72 h) of tumor development. The time points in hours represent 
the time points after i.v. injection of 100 µl PBS as infection control. Data are represented as median and 
range from n=2. 
Altogether, between tumors of uninfected and with P. aeruginosa infected mice, two main 
differences according to the detected chemokine concentrations existed. Firstly, tumors of 
uninfected mice contained detectable concentrations of all five chemokines tested (Figure 
24). Secondly, in such tumors existed five chemokine gradients with increasing 
concentrations from the circulation into the tumor, at the individual time points. Whereas 
in infected mice, only the MIP-2 / CXCL-2 gradient was detected with the potential to 
attract neutrophils into the tumor (Figure 23, p.46).   
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3.4.1 Phenotypical characterization of TAN populations 
Neutrophils in tumors are often polarized into the direction of anti-inflammatory N2 cells. 
However, in the present situation the normal tumor development is disturbed by the 
presence of an enlarged necrotic region as well as bacteria which might influence the 
polarization of neutrophils. Therefore, tumors were investigated by digestion of tumor 
tissues and subsequent flow cytometry. To standardize the analysis, always the same 
gating strategy was used (Figure 25A-J, p.49). As a second control group besides untreated 
tumors and to mimic extrinsic inflammatory effects, tumor-bearing mice were i.v. treated 
with 1 µg / 100 µl of recombinant TNF-α.  
First of all, the total number of TANs which infiltrated the tumors of differentially treated 
WT mice was investigated. Within untreated (PBS) tumors, the total number of TANs 
amounted to 106 neutrophils / gram tumor and was uniform on day 11 and day 13 of 
tumor growth (Figure 26A+C, p.50). The neutrophil influx on day 1 p.t. with PA14 or TNF-α 
was comparable to that (Figure 26B, p.50), whereas at day 3 p.t. the total number of TANs 
per tumor was significantly higher in the two treated groups (Figure 26D, p.50).  
However, not only the number of TANs, but rather their functional specialization is 
supposed to be influenced by the various conditions within the tumor microenvironment. 
While CT26 tumors continually grew on untreated BALB/c mice, they started to shrink 
immediately after infection with P. aeruginosa PA14 (Figure 13, p.35) or TNF-α-treatment 
[122]. Therefore, TANs inside the different tumor microenvironments were analyzed for 
the distinct expression of diagnostic markers of polarization, like surface molecules and 
cytokines, on day 11 and 13 of tumor growth. Although the number of TANs in tumors of 
untreated (PBS) and treated (PA14, TNF-α) animals at day 1 p.t. was similar (Figure 26A+B, 
p.50), the expression of phenotyping markers was different after treatment (Figure 27A, B, 
D, p.51). The bacterial infection or TNF-α-injection induced both the following phenotypic 
changes (Figure 27B-E, p.51): significant more TANs expressed Icam and Fas, but less cells 
produced TNF-α at the same time. Only after infection the number of TANs with active 
caspase 3 was additionally increased. These changes represented obvious phenotypic 
switches of the TAN population after treatment.  
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Figure 25: Detection strategy and phenotyping scheme for neutrophils in tumor lysates 
The depicted gating strategy was used in BD FACSDiva to identify live Pacific Blue
-
 CD45
+
 CD11b
+
 Ly6G
+
 
neutrophils (A-E) out of tumor lysates, exemplified here by a PBS-treated tumor from WT mice 1 d p.t.. In 
general, after 10 d of tumor growth the mice were i.v. treated with PBS / P. aeruginosa WT PA14 / 1 µg 
recombinant TNF-α and neutrophils (pink contours) were analyzed 1 d or 3 d p.t. for their phenotypic 
specialization by measurement of the percentage of marker
 
positive neutrophils within the TAN population 
(F-J). The numbers of positive cells were indicated as percentage from the parental population which was 
selected one gating step before. 
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Figure 26: Total number of TANs / tumor (g) in WT mice 1 d and 3 d p.t. 
The total number of TANs was investigated after 11 d (A+B) and 13 d (C+D) of tumor growth. After 10 d, 
tumor-bearing BALB/c mice were i.v. treated with PBS / 5.7x10
6
 P. aeruginosa WT PA14 / 1 µg recombinant 
TNF-α. Total cell numbers were achieved in three steps: (i) cell counting in a Neubauer chamber using a light 
microscope, (ii) correlation of this number with the percentage of live (Pacific Blue
-
) cells in the 
corresponding FACS analysis, and (iii) calculation of the respective number of neutrophils (Pacific Blue
-
 
CD45
+
 CD11b
+
Ly6G
+
) out of the percentage within the FACS analysis. To consider variations in in vivo tumor 
sizes, neutrophil numbers are depicted per gram tumor. Data are represented as median from n=3-4. For 
statistical analyses the Mann Whitney test, one-tailed, *p<0.05 was used to compare total TAN numbers of 
treated mice with the PBS group. Groups were analyzed in 2 independent experiments. 
On day 3 p.t., the number of active caspase 3+ and CD62L+ TANs within tumors of 
untreated mice was reduced (Figure 28A, p.52) compared to day 1 p.t. (Figure 27A, p.51). 
Furthermore, the number of markers which were differentially expressed in treated mice 
compared to untreated animals decreased from 3-4 markers (Figure 27C+E, p.51) to 1-2 
markers (Figure 28C+E, p.52). The percentage of Icam+ and active caspase 3+ TANs was 
significantly higher in infected tumors (Figure 28C), whereby TNF-α treatment activated 
more TANs to produce active caspase 3 (Figure 28E).  
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Figure 27: TAN phenotype 1 day p.t. of WT mice 
The phenotype of TANs in tumors was investigated 1 d p.t. of WT mice with PBS (A) / 5.7x10
6
 P. aeruginosa 
WT PA14 (B+C) / 1 µg recombinant TNF-α (D+E). The percentage of Dapi
-
 CD45
+
 CD11b
+
 Ly6G
+
 cells (TANs) 
expressing the extracellular proteins Icam, Fas, CD62L and the intracellular cytokines TNF-α and active 
caspase 3 was investigated by FACS analyses of tumor lysates. Data are represented as median from n=3-4. 
For statistical analyses the Mann-Whitney test, one-tailed, *p<0.05 was used to compare the percentage of 
marker
 
positive TANs in tumors of treated mice with the PBS group (C, E). For CD62L the values on the y-axis 
have to be read with the algebraic sign vice versa (C, E). Groups were analyzed in 2 independent 
experiments. 
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Figure 28:TAN phenotype 3 days p.t. of WT mice 
The phenotype of TANs in tumors was investigated 3 d p.t. of WT mice with PBS (A) / 5.7x10
6
 P. aeruginosa 
WT PA14 (B+C) / 1 µg recombinant TNF-α (D+E). The percentage of Dapi
- 
CD45
+
 CD11b
+
 Ly6G
+
 cells (TANs) 
expressing the extracellular proteins Icam, Fas, CD62L and the intracellular cytokines TNF-α and active 
caspase 3 was investigated by FACS analyses of tumor lysates. Data are represented as median from n=3-4. 
For statistical analyses the Mann-Whitney test, one-tailed, *p<0.05 was used to compare the percentage of 
marker
 
positive TANs in tumors of treated mice with the PBS group (C, E). For CD62L the values on the y-axis 
have to be read with the algebraic sign vice versa (C, E). Groups were analyzed in 2 independent 
experiments. 
Altogether, compared to untreated mice several phenotypes of the TAN population 
shifted on day 1 and day 3 p.t. with P. aeruginosa or TNF-α. More TANs expressed pro-
inflammatory markers, though the whole populations became more N1-like in WT mice. 
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Within the tumor microenvironment a lot of other immune cells exist besides TANs. 
Especially T-lymphocytes are able to decisively influence tumor growth. If the presence of 
T cells also affects the phenotypes of the TAN population or whether the TAN phenotypes 
are independent of T cell signals was examined in Rag1-/- mice. First, the general influx of 
neutrophils into such tumors was investigated. The total number of TANs in untreated 
tumors was about 105 TANs / gram tumor and about 106 TANs / gram in treated tumors 
(Figure 29A+C). This was 10-fold lower than in WT animals (Figure 26A+C, p.50) under the 
respective conditions. However, in contrast to WT mice, the number of TANs in tumors 
was significantly increased 1 d p.t. with TNF-α (Figure 29B) compared to PBS. The number 
of TANs in PBS-treated and infected tumors was similar on day 1 and 3 p.t. (Figure 29B+D). 
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Figure 29: Total number of TANs / tumor (g) in Rag1
-/-
 mice 1 d and 3 d p.t. 
The total number of TANs was investigated after 11 d (A+B) and 13 d (C+D) of tumor growth. After 10 d, 
tumor-bearing Rag1
-/-
 mice were i.v. treated with PBS / 5.3x10
6
 P. aeruginosa WT PA14 / 1 µg recombinant 
TNF-α. Total cell numbers were achieved in three steps: (i) cell counting in a Neubauer chamber using a light 
microscope, (ii) correlation of this number with the percentage of live (Pacific Blue
-
) cells in the 
corresponding FACS analysis, and (iii) calculation of the respective number of neutrophils (Pacific Blue
-
 
CD45
+
 CD11b
+
Ly6G
+
) out of the percentage within the FACS analysis. To consider variations in in vivo tumor 
sizes, neutrophil numbers are depicted per gram tumor. Data are represented as median from n=4-5. For 
statistical analyses the Mann-Whitney test, one-tailed, *p<0.05 was used to compare total neutrophils 
numbers in tumors of treated mice with the PBS group. Groups were analyzed in 2 independent 
experiments. 
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To examine, whether T cells influence the phenotype of the TAN population, the 
percentages of marker positive TANs were also analyzed in tumor-bearing Rag1-/- mice 
treated with PBS, P. aeruginosa or TNF-α (Figure 30 and Figure 31, p.55).  
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Figure 30: TAN phenotype 1 day p.t. of Rag1
-/-
 mice 
The phenotype of TANs in tumors was investigated 1 d p.t. of Rag1 
-/-
 mice with PBS (A) / 5.3x10
6
 
P. aeruginosa WT PA14 (B+C) / 1 µg recombinant TNF-α (D+E). The percentage of live Pacific Blue
-
 CD45
+
 CD11b
+
 Ly6G
+
 TANs expressing the extracellular proteins Icam, Fas, CD62L and the intracellular 
cytokines TNF-α and active caspase 3 was investigated by FACS analyses of tumor lysates. Data are 
represented as median from n=4. For statistical analyses the Mann-Whitney test, one-tailed, *p<0.05 was 
used to compare the percentage of marker
 
positive TANs in tumors of treated mice with the PBS group (C, 
E). For CD62L the values on the y-axis have to be read with the algebraic sign vice versa (C, E). Groups were 
analyzed in 2 independent experiments. 
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Figure 31: TAN phenotype 3 day p.t. of Rag
-/-
 mice 
The phenotype of TANs was analyzed 3 d p.t. of Rag1
-/-
 mice with PBS (A) / 5.3x10
6
 P. aeruginosa WT PA14 
(B+C) / 1 µg recombinant TNF-α (D+E). The percentage of live Pacific Blue
-
 CD45
+
 CD11b
+
 Ly6G
+
 TANs 
expressing the extracellular proteins Icam, Fas, CD62L and the intracellular cytokines TNF-α and active 
caspase 3 was investigated by FACS analyses of tumor lysates. Data are represented as median from n=4-5. 
For statistical analyses the Mann-Whitney test, one-tailed, *p<0.05 and **p<0.01 were used to compare the 
percentage of marker positive TANs in tumors of treated mice with the PBS group (C, E). For CD62L the 
values on the y-axis have to be read with the algebraic sign vice versa (C, E). Groups were analyzed in 2 
independent experiments. 
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The expression profiles of the neutrophil phenotyping markers in PBS-treated tumors in 
Rag1-/- mice were the same as in WT mice at day 1 p.t. (Figure 27A, p.51, Figure 30A, p.54): 
about 90% of all TANs expressed the intracellular pro-inflammatory cytokine TNF-α, 80% 
the apoptosis receptor Fas, 50% the leukocyte homing ligand CD62L, and approximately 
30% were positive for Icam and active caspase 3. On day 3 p.t. the expression profile in 
Rag1-/- mice showed an increased number of active caspase 3+, Icam+, and Fas+ TANs, and 
a decreased TNF-α+ TAN number as in WT animals (Figure 28A, p.52, Figure 31A, p.55). 
Tumor-bearing Rag1-/- animals which had received bacteria or recombinant TNF-α i.v. 
showed identical marker expression profiles at day 1 p.t. (Figure 30B+D, p.54). 
Consequently was the variation of marker positive TANs compared to PBS-treated animals 
also the same (Figure 30C+E, p.54): the number of neutrophils expressing Icam and Fas on 
their cellular surface increased significantly after injecting bacteria or recombinant TNF-α 
into Rag1-/- mice, whereas the drop in TNF-α+ as well as the rise in active caspase 3+ or 
CD62L+ TANs was only minor. In the respectively treated tumor-bearing WT animals, the 
marker expression profiles of marker positive TANs were also identical after P. aeruginosa 
or TNF-α injection (Figure 27B+D, p.51). 
Three days after the treatment of Rag1-/- mice with P. aeruginosa or TNF-α the marker 
expression profiles were different for the two treatment groups in comparison to the PBS 
group (Figure 31C+E, p.55): whereas the complete profile changed highly significantly for 
all five markers after infection of tumor-bearing Rag1-/- mice, only the number of Icam+ 
and active caspase 3+ TANs differed after TNF-α injection. Nevertheless, in principal were 
the tendencies after TNF-α injection similar to the one after P. aeruginosa treatment, but 
the significances were lower. Differences between day 1 and day 3 p.t. were, that more 
cells of the TAN population in infected or TNF-α-treated tumors produced TNF-α, active 
caspase 3, and CD62L in comparison to PBS-injected Rag1-/- mice on day 3 p.t.. These 
marker profiles differed from WT mice (Figure 28, p.52), as more cells after infection and 
less TANs after TNF-α injection showed an upregulation of their markers in Rag1-/- mice.  
All in all was the induced phenotypic switch of the tumor-associated neutrophil 
population most dramatic in Rag1-/- mice 3 days p.i. with P. aeruginosa (Figure 31C, p.55). 
Up to 40 % of the cells started to produce active caspase 3, or to show Icam or CD62L on 
their surface, 20 % more TANs generated TNF-α, and about 10 % more TANs were positive 
for Fas. All five variations to PBS-treated tumor-bearing Rag1-/- mice were highly 
significant with p<0.01. The correlating phenotypic switch in infected tumors on WT mice 
was less decisive (Figure 28C, p.52).  
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But interestingly, in WT mice was the phenotypic switch of the TAN population on 3 days 
p.t. with TNF-α more pivotal than in Rag1-/- mice (Figure 28E, p.52 and Figure 31E, p.55): 
the amount of active caspase 3+ TANs increased about 60 % in tumors on WT mice and 
only up to 10 % in tumors on Rag1-/- mice. 
However, the injection of P. aeruginosa or TNF-α did induce phenotypic switches in the 
respective TAN populations in tumor-bearing WT as well as Rag1-/- mice. Tumors on these 
mice injected with PBS contained the lowest percentages of marker positive TANs and 
reflected therefore N2 phenotypes of the TAN populations. This was compatible with the 
detected continuing tumor growth on such mice (Figure 16, p.38 and later Figure 33, 
p.59). After infection or TNF-α treatment, the TAN populations contained more pro-
inflammatory cells. Therefore their phenotypes shifted to N1. But since only tumors on 
WT mice started to shrink after treatment (Figure 15, p.37), the sole presence of a natural 
amount of anti-tumor-polarized N1 TANs seemed to be not sufficient to induce tumor 
rejection in our model. 
 
3.4.2 Neutrophil polarizing cytokines and -hypoxia 
It is known that the tumor microenvironment itself stimulates neutrophils to specialize 
towards a certain phenotype. The cytokines G-CSF, IL-4, IL-10, and MCP-1 / CCL-2 as well 
as hypoxic conditions inside the tumor may favor the development of pro-tumor (N2) 
functions in neutrophils, whereas the cytokines IFN-β, IFN-γ, and GM-CSF are known to 
stimulate anti-tumor (N1) functions. Anti-inflammatory N2 neutrophils represent the 
usual TAN phenotype in growing tumors. The emergence of for example an inflammatory 
tumor microenvironment can result in a phenotypic switch of TANs into pro-inflammatory 
N1 neutrophils.  
The existence of N2- or N1-stimulating cytokines was investigated in tumor lysates of 
growing tumors from PBS-treated and of shrinking tumors from P. aeruginosa infected WT 
mice (Figure 32A+B, p.58). Within both kinds of treated tumors were only three of the six 
analyzed cytokines present at a concentration above 50 pg/ml: the N2-promoting 
molecules G-CSF and MCP-1 / CCL-2, and the N1-stimulating cytokine GM-CSF. In growing 
tumors compared to infected shrinking tumors, the concentration of (i) G-CSF was about 
327-fold increased (day 3 p.t.), (ii) MCP-1 was about 13- (day 1 p.t.) to 93-fold (day 3 p.t.) 
increased, and (iii) GM-CSF was about 6-times higher (day 3 p.t.).  
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Figure 32: Neutrophil polarizing cytokines in WT tumor microenvironments 
Luminex analyses were performed on tumor lysates 1 d and 3 d p.t. of BALB/c WT mice with PBS (A) or 5x10
6
 
P. aeruginosa (B). The black bars represent cytokines which stimulate a polarization of neutrophils into 
tumor-supportive N2 TANs. Whereas the white bars indicate pro-inflammatory cytokines which favour 
tumor-suppressive N1 TAN functions. Arrows indicate a decreased concentration of N2-stimulating 
molecules in infected tumors (B). Data are represented as median and range from n=2. 
Furthermore, the cytokine IFN-β is known to induce the polarization of N1 TANs, which 
were detected in shrinking tumors of infected WT mice (Figure 27C, p.51 and Figure 28C, 
p.52). Since the N1-supporting cytokines GM-CSF and IFN-γ were not present in shrinking 
tumors on day 1 and day 3 p.i. in high concentrations (Figure 32B), the intra-tumoral 
availability of IFN-β was investigated by in vivo imaging using a recently introduced 
reporter system [137]. The three representative IFN-β+/∆β-luc mice illustrated in Figure 33, 
p.59 were bearing CT26 solid tumors, which were by them not able to produce a light 
signal after luciferin application. The detection of light emission was therefore a clear 
result for the actual availability of IFN-β produced by the host cells. Mice which received 
PBS gave already a slight, steady and local light signal over time, which indicated the 
presence of IFN-β in the naïve tumor microenvironment. From these observations the  
IFN-β signal-intensity varied only at the first measurement after treatment of mice with 
recombinant TNF-α. Nevertheless, the signal at 0 h was already rather high and locally 
defined within the tumor center under these treated condition. Afterwards, the IFN-β 
intensity was the same as in PBS-treated mice. 
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Figure 33: IFN-ß secretion in 
tumor-bearing IFN-ß reporter 
mice 
Luciferase activity was 
measured in tumor-bearing  
IFN-β
+/∆β-luc
 mice at several time 
points after i.v. injection of PBS, 
1,97x10
7
 P. aeruginosa WT 
PA14, or 1 µg recombinant  
TNF-α. The time point 0 h 
indicates the first measurement 
directly after the respective 
injection, performed at day 10 
of tumor growth. At every time 
point the 2-3 mice per group 
were injected with luciferin, 
anesthetized, and monitored on 
the abdomen- and left body-
side for IFN-β specific light 
emission by an IVIS 200 whole 
body imaging system. One 
representative mouse per 
group is depicted over time. 
The infection with P. aeruginosa on the contrary highlighted an increase in the IFN-β 
expression (Figure 33). Almost the entire infected mice were emitting light, indicating a 
systemic production of IFN-β throughout the body. Centers of the signal were at 4 h p.i. in 
the lower abdomen and spleen, whereas at 22 h p.i. the signal was detected in the 
complete abdomen and furthermore accumulated in the tumor center. 
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Afterwards the intensity of IFN-β decreased slightly within the infected mice, but stayed 
prominent within the tumor center. The concentration of IFN-β inside infected, shrinking 
tumors was much higher as in PBS-treated, growing tumors. Therefore, the amount of 
expressed IFN-β might have been able to induce the detected phenotypic switches from 
N2 towards N1 TANs in infected mice. 
On the other hand, a prominent factor which influences neutrophil polarization into 
tumor-supportive N2 cells is the occurrence of hypoxia inside tumors. Solid tumors tend to 
develop hypoxic regions due to their leaky vascular system and the limited distribution of 
oxygen in less vascularized tumor sites. When neutrophils reside in hypoxic tumor areas, 
the cells could be influenced by the low oxygen conditions to fulfill tumor-promoting 
functions. In Figure 20, p.43 it was already shown that TANs resided between the viable 
and necrotic tumor tissue. In follow-up experiments, infected mice were i.v. treated with 
pimonidazole to highlight hypoxic regions within the tumor by immunohistochemistry. 
The tumor in Figure 34A, p.61 was analyzed 3 days p.i. with P. aeruginosa and mirrored 
the organization of viable, granulocytic, and necrotic cells like depicted in Figure 20A, 
p.43, even though the sample was technically disrupted in the upper tumor part. The 
distribution of hypoxic areas inside the infected tumor was limited to a cellular band 
between viable tumor cells and live tumor-associated neutrophils (Figure 34B, p.61).  
To examine the distribution of the various cell types in more detail, further consecutive 
tumor sections were stained with additional antibodies and a part of the tumor which 
includes hypoxic staining was taken for comparable analysis at a higher magnification 
(Figure 35, p.62). Underneath the mouse skin resided viable tumor cells which were able 
to divide, as indicated by Ki67 expression, and probably drive tumor growth (Figure 
35A+D). The boarder for sufficient oxygen availability started underneath, even before the 
zone of tumor infiltrated neutrophils began (Figure 35B+C). Within the band of 
neutrophils were some slight signals for hypoxia (Figure 35C), but most of the area 
seemed to be anoxic. The density of proliferating cells decreased within the areas of 
hypoxia and TANs, and the subjacent necrotic tumor zone did not show any signal of cell 
proliferation (Figure 35D). Colonization of P. aeruginosa was detected mainly directly 
under the mouse skin between viable tumor cells, and to a low degree between the 
granulocytic band and necrotic tumor area (Figure 35E). Tumor-associated neutrophils 
obviously colonized tumor regions with very low oxygen levels, where they might also co-
localize with bacteria. 
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Figure 34: Hypoxic areas arise between 
the viable and granulocytic tumor area 
The CT26 tumor on a BALB/c WT mouse 
was collected 3 days p.i. with 5.7x10
6
 
P. aeruginosa and several consecutive 
sections were prepared. Sections were 
stained with A: Hematoxylin-and-eosin 
to highlight viable (V) and necrotic (N) 
tumor regions. Tumor infiltrating cells, 
mainly neutrophilic granulocytes (G), are 
indicated as dark purple cells with intact 
nuclei. Around the tumor is the mouse 
skin (S). The incrusted host skin and the 
subjacent loose viable tumor tissue were 
partially disrupted due to technical 
issues. B: Staining with diamino-
benzidine-pimonidazole (PAb2627AP 
0.5mg/ml IgG) to detect hypoxic areas 
with an oxygen concentration lower 
than 14 mM or pO2 of 10 mm Hg at 37°C 
(H). The images were made 
transparently, and put on top of each 
other to label exactly the same areas 
and to demonstrate relative proximity. 
The arrow outside the viable tumor 
zone highlights the point of orientation 
for the detailed analyses depicted in 
Figure 35, p.62. 
 
 
 
A 
B 
62      Results  
 
 
 
 
 
 
 
  
 
Figure 35: TANs reside between necrotic and hypoxic tumor zones 
Detailed analyses of Figure 34, p.61. The arrow outside the tumor highlights the point of orientation. The 
CT26 tumor on a BALB/c WT mouse was collected 3 days p.i. with 5.7x10
6
 P. aeruginosa and several 
consecutive sections were made. Sections were stained with A: Hematoxylin-and-eosin to highlight viable 
(V) and necrotic (N) tumor regions, B: diaminobenzidine-pimonidazole (PAb2627AP 0.5mg/ml IgG) to detect 
hypoxic areas (H) with an oxygen concentration lower than 14 mM or pO2 of 10 mm Hg at 37°C, C: 
diaminobenzidine-myeloperioxidase to highlight neutrophilic granulocytes (G), D: diaminobenzidine-Ki67 to 
detect proliferative and dividing cells (D), E: diaminobenzidine-P. aeruginosa to visualize bacterial 
colonization (P). The images were made transparently, and put on top of each other to label exactly the 
same areas in all pictures and to demonstrate relative proximity. 
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Previous results demonstrated the infiltration of neutrophils also into uninfected tumors 
(Figure 26A+C, p.50). In contrast to bacterial infected or TNF-α treated mice, tumors of 
PBS-treated mice showed on day 13 of tumor development (= d3 p.i./p.t.) large and 
distinct patterns of hypoxia throughout the huge viable tumor zone (Figure 36A+B). This 
hypoxic pattern was also present in 11 day old tumors of PBS-treated mice (= d1 p.i.), and 
surprisingly as well in tumors of mice treated with P. aeruginosa or TNF-α at 1 day p.i./p.t.. 
Besides that, the necrotic tumor zone in the PBS-treated growing tumors was much 
smaller than in shrinking tumors of infected or TNF-α-treated mice (Figure 34B, p.61). The 
tumor-associated neutrophils within untreated tumors resided within the same area as in 
treated tumors, between hypoxic and anoxic tumor zones (results not shown).  
 
 
Figure 36: Uninfected tumors show extensive hypoxic patterns in the large viable tumor zone 
The CT26 tumor on a BALB/c WT mouse was collected 3 days p.t. with PBS, started after 10 d of tumor 
growth. Several consecutive sections were cut and stained with A: Hematoxylin-and-eosin to highlight viable 
(V) and necrotic (N) tumor regions. Around the tumor was the mouse skin (S). This and the subjacent loose 
viable tumor tissue were partially disrupted due to technical issues, B: diaminobenzidine-pimonidazole 
(PAb2627AP 0.5mg/ml IgG) to detect hypoxic areas (H) with an oxygen concentration lower than 14 mM or 
pO2 of 10 mm Hg at 37°C. The images were made transparently and put on top of each other to label exactly 
the same areas. 
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3.5 Co-localization of TANs and P. aeruginosa biofilms inside tumors 
It was an obvious question whether such pro-inflammatory N1 neutrophils inside infected 
tumors on WT mice (Figure 28B+C, p.52) are able to destroy the pathogens by 
phagocytosis. This was investigated by transmission electron microscopy (TEM) of tumor 
sections. Indeed, the multinucleated TANs were able to phagocytose some bacteria 
(Figure 37A+B) close to the necrotic tumor zone, where most of P. aeruginosa reside as 
single bacteria (Figure 38). 
  
Figure 37: Phagocytosis of P. aeruginosa by TANs 
BALB/c WT mice were s.c. injected with CT26 cells and after 10 days of tumor growth i.v. infected with 5x10
6
 
P. aeruginosa WT PA14. Tumors were processed 3 d p.i. and prepared for transmission electron analyses. 
Single bacteria (black arrow) were detected inside the multinucleated tumor-associated neutrophils (A+B). 
 
Figure 38: P. aeruginosa single bacteria reside close 
to the necrotic tumor zone 
BALB/c WT mice were s.c. injected with CT26 cells 
and after 10 days of tumor growth i.v. infected with 
9.3x10
6
 P. aeruginosa WT PA14. Tumors were 
prepped 3 d p.i.. Cryosections were fixed in -20°C 
acetone and stained for AA-Lectin (blue) and 
P. aeruginosa (green) depicted as merged picture. 
B 
2 µm 1 µm 
A 
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Interestingly, no sign of bacterial stress was observed under such conditions (Figure 37, 
p.64). Most likely neutrophils are unable to harm the bacteria under such low oxygen 
conditions before phagocytosis. 
Whether TANs were like bacteria also localized within the viable and proliferative part of 
solid tumors was furthermore analyzed by histology on cryosections.  
 
 
 
  
Figure 39: Co-localization of TANs and P. aeruginosa in the viable tumor zone 
BALB/c WT mice were s.c. injected with CT26 cells and after 10 days of tumor growth i.v. infected with 1x10
6
 
P. aeruginosa. Tumors were prepped 3 d p.i.. Cryosections were fixed in -20°C acetone and stained for 
CD11b (blue), Gr-1 (red), and P. aeruginosa (green) depicted as merged pictures (A+B). Further tumors were 
prepared for transmission electron analyses (C). Enlargement of the dotted frame, rotated in D. Tumor-
associated neutrophils (pink circle in C or pink arrow in D) and bacterial clusters (green arrows in C and D) 
were detected directly under the mouse skin (S) in C. 
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TANs obviously resided also directly under the mouse skin (Figure 39A+C, p.65). There 
they co-localized with the invaded pathogens, which existed as several clusters in the 
viable tumor area (Figure 39B, p.65). In more detail, these clusters represented 
accumulations of 30 to 60 single bacteria embedded within a fibrous biofilm matrix (Figure 
39C+D, p.65) as described before [139]. Phagocytosis of such bacterial clusters, which 
display a multiple size of TANs, was not detected. The bacteria were obviously under 
severe stress as indicated by the extensive plasma lysis of most of the bacteria. Such 
biofilms were also detected to similar degrees when P. aeruginosa colonized tumors from 
Rag1-/- mice (Figure 40). 
 
 
 
  
Figure 40: P. aeruginosa biofilm formation in tumors on Rag1
-/-
 mice 
Rag1
-/-
 mice were s.c. injected with CT26 cells and after 10 days of tumor growth i.v. infected with 9.3x10
5
 
P. aeruginosa. Tumors were prepped 3 d p.i. and prepared for transmission electron analyses. Bacterial 
clusters were embedded in loose (A) or dense (B) extracellular matrix material, depending on the distance of 
the clusters to the host skin (S) in C. A+B are enlargements of the dotted areas is C. Scale bars 500 nm (A+B) 
or 5 µm (C). 
 
All in all P. aeruginosa was able to form biofilms inside the tumor tissues and survive the 
attacks of the pro-inflammatory N1 TANs, in immunocompetent as well as in 
immunocompromised animals. However, only WT mice were able to clear CT26 tumors 
after bacterial infection due to specific T cell functions. 
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4 Discussion 
In face of the rising incidence of cancer, the search for therapeutic strategies alternative 
to such that are presently in routine use is a mandatory enterprise in biomedical research. 
The employment of pathogenic bacteria for the treatment of solid tumors appears highly 
promising in this context. Most extensively Salmonella spp. and Clostridia spp. are 
investigated. However, other so far not explored bacteria might possess therapeutic 
properties that are more appropriate than such of the microorganisms above. Thus, 
P. aeruginosa was tested in the present work for the treatment of murine solid tumors. 
 
4.1 Tumor size and infection dose are decisive parameters of the model 
During tumor development, tumor cells secrete angiogenic factors that enable the 
establishment of a tumor neovascularization. Since these tumor-associated blood vessels 
serve as port of entry for the bacteria into the tumor tissue, angiogenesis and the time 
thereof prior to infection might be very important for tumor colonization. The extent of 
the tumor neovasculatur system will be reflected in the size of the tumor. Thus, by 
applying P. aeruginosa into mice bearing tumors of different sizes, the optimal tumor size 
for the day of infection was determined. When tumors were allowed to develop for ten 
days and accordingly exhibiting a volume of about 100-150 mm³, they showed a 
consistent and reliable colonization by P. aeruginosa. Tumors of smaller size were 
inconsistently colonized or even not at all. The vascularization of fast growing tumors is 
pathological and might be causatively involved in tumor invasion by the bacteria [116]. 
Thus, sufficient time might be required to develop such blood vessels. On the other hand, 
the tumor influences the hematopoietic cells. Thus, during early tumor growth, the 
cytokine storm elicited by the application of the bacteria might be different under such 
conditions. More investigation will be required to understand this phenomenon. Since this 
type of therapy is also intended to clear metastases which will be of small size, this is an 
important question to answer. 
Interestingly, the extent of colonization of the tumor tissue was dependent on the size of 
the bacterial inoculum. This was largely different from what was observed when using 
Salmonella (Leschner S., unpublished). The optimal infection dose for CT26 tumor-bearing 
BALB/c mice was determined to be 5x106 P. aeruginosa. Mice infected with the highest 
concentration of bacteria suffered under the infection conditions, probably due to a 
dramatic cytokine storm and a high colonization of organs like liver and gut. Nevertheless, 
the colonization by P. aeruginosa never reached the levels that were observed with 
Salmonella and E. coli. 
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Thus, the tumor niche for P. aeruginosa might be smaller and dependent on the number 
of bacteria applied. On the other hand, Pseudomonas is not truly anaerobic. Hence, the 
various environments within a tumor, especially the anoxic tumor core, might be only to a 
limited extend suitable for P. aeruginosa. 
Shortly after application of the bacteria into tumor-bearing mice, the tumors changed 
their visible phenotype from red to a dark color. Apparently a hemorrhage was taking 
place. Over the experimental time course, the tumor surface became necrotic and a black 
crust developed. Previous experiments using S. Typhimurium have yielded similar results 
[116]. The influx of blood is most likely induced by the secretion of pre-stored TNF-α from 
myeloid cells upon systemic application of the bacteria. The molecule TNF-α is known to 
be a vasoactive cytokine that might exhibit a particular strong reaction on the pathological 
endothelia of the tumor and thereby causing increased leakiness of the tumor-associated 
blood vessels. 
 
4.2 The priming of CD4
+
- and CD8
+
 T cells is essential for the anti-tumor effect 
When tumor-bearing WT mice were infected with P. aeruginosa the tumors did not only 
change their color, they moreover started to shrink and disappeared within 13 days p.i.. 
The CT26 tumor cell line is highly immunogenic and previous studies demonstrated that 
effector T cells of BALB/c WT mice are able to infiltrate tumors in high numbers from day 7 
of tumor growth onwards via the circulation [140, 141]. Such anti-tumor effector T cells 
are probably activated due to an adjuvant effect after i.v. administration of bacteria like 
Salmonella or E. coli [122], which induces the infiltration of tumors by such effector T cells 
[111]. To test, whether this also holds true for the application of P. aeruginosa, WT mice 
that had cleared the CT26 tumor after infection were re-challenged with CT26 tumor cells 
and simultaneously with F1A11 fibrosarcoma cells as control. The observed clearance of 
only CT26 tumors and the concurrent unrestricted growth of F1A11 tumors on the same 
mouse revealed specificity and immune memory. These two criteria are characteristic for 
an immune reaction. 
The important role of the specific immune system against CT26 tumors after bacterial 
infection was confirmed when tumor-bearing Rag1-/- mice were treated with 
P. aeruginosa. The infected immunocompromised mice were not able to retard tumor 
growth at all. Such mice are deficient for CD4+ and CD8+ T  cells, which are well known to 
develop anti-cancer functions [39, 142].  
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To characterize this reaction in more detail, the impact of differentially primed total 
T cells, like they should occur during the course of infection of tumor-bearing WT mice 
was investigated by adoptive transfers. Rag1-/- mice were reconstituted with T cells and at 
the same time CT26 cells were applied. No effect was detected after the transfer of naïve 
total T cells as expected. Interestingly, reconstitution of Rag1-/- mice by total T cells 
isolated from uninfected but tumor-bearing mice resulted in tumor growth retardation. 
Apparently, already in such mice specific anti-tumor T cells were present although the 
tumor was still growing. This situation is reminiscent of human cancer patients in which 
tumor-specific T cells are observed. However they are not able to fight the neoplasia. In 
addition, the transfer of total T cells from infected mice that had cleared their tumors 
caused tumor rejection in all the recipient mice. 
As a next step it was of interest, whether CD4+- and/or CD8+ effector T cells are 
responsible for clearance of CT26 tumors. Therefore CD4+- or CD8+ T cells as well as total 
T cells from mice treated in different ways were adoptively transferred into Rag1-/- mice 
together with CT26 cells. Whereas the transfer of naïve total T cells did not show any 
effect again, total T cells isolated from uninfected tumor-bearing WT mice were able to 
clear CT26 tumors in 75 % of the cases within 21 days. Probably, the final number of 
effector T cells was still limiting such that the tumors grew in some mice, causing only a 
retardation of tumor growth in the preceding experiment. However, these total T cells 
have been isolated out of uninfected tumor-bearing WT mice in which they were not able 
to induce tumor growth retardation, even though they had obviously encountered tumor 
antigens and became tumor-antigen specific. Probably, the 12 day old tumor had 
developed immune-escape mechanisms through which the T cells were not able to 
influence the tumor development anymore. Since the adoptive T cell transfer into Rag1-/- 
mice was done simultaneously with the injection of tumor cells, the potentially tumor-
antigen specific effector T cells could have targeted the cancer cells before these 
developed immune-escape mechanisms. To inhibit the function of effector T cells, tumors 
are supposed to activate several inhibitory checkpoint pathways in the immune cells, like 
through the expression of the PD-1 ligand or CTLA-4 ligands [143]. Nevertheless, it might 
explain the efficient induction of anti-tumor immunity when bacteria are applied. The 
adjuvant properties of such microorganisms are supposed to act on preexisting immune 
cells of the tumor-bearing host. 
None of the isolated CD4+- or CD8+ T cells out of uninfected tumor-bearing WT mice were 
able to reject CT26 tumors after transfer. Because the cell numbers of transferred cells 
were similar for total and single T cells, and the sample of total T cells comprised a mixture 
of the isolated single positive cells, a reduced number of effector T cells within the CD4+- 
or CD8+ population was unlikely.  
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It was more likely that a synergy due to CD4+-CD8+ T cell cooperation was responsible for 
the observed effect. It was demonstrated recently that the cytokine IFN-γ, which is 
supposed to be essential for the cytotoxic activity of CD8+ T cells [139], was produced by 
isolated effector CD4+ T cells after seven days of CT26 tumor growth [141]. On the other 
hand, the CTLs may have experienced licensing, through the activation of APCs by CD4+ 
Th cells which in turn trigger and activate CD8 T cells [39, 144]. to carry out sufficient 
cytotoxic anti-tumor functions.  
When total T cells from WT mice which had cleared CT26 tumors after infection were 
transferred into Rag1-/- mice, the animals cleared the tumors within 13 days after transfer. 
The same was true when only CD8+ T cells from such mice were transferred. Such CD8+ 
memory T cells might have been able to autonomously expand in numbers after re-
encountering the same tumor-antigens and to kill the tumor cells. This feature of CTLs has 
been demonstrated in previous studies using several mouse models. They showed that 
effector CD8+ T cells were able to maintain their anti-tumor functions in the absence of 
CD4+ T cells [145]. And furthermore, that transgenic CT26 tumors which have developed 
on BALB/c mice were rejected by the CTLs once they had completed their specialization 
[141]. Interestingly, under such conditions also isolated CD4+ T cells reduced the tumor 
size significantly from day 8 p.t. onwards, although they were not able to clear the tumors 
completely. Similarly, in the study mentioned above CD4+ T cells were not able to 
completely reject newly developed transgenic CT26 tumors [141]. In further studies it was 
shown that primed CD4+ T cells were indeed able to eliminate cancer cells in CD8+ T cell 
deficient hosts by for example the secretion of TNF-α [39, 146]. This could be extended to 
the present study by for instance digestion of tumors and subsequent FACS analyses, or 
immune histology of tumor cryosections. Additionally, the secretion of enzymes like 
granzyme-B or perforin by the tumor-specific CD4+ T cells could be tested. Such molecules 
were described to be employed by immune cells to kill neoplastic cells [142, 147]. 
 
4.3 TANs infiltrate tumors with prominent MIP-2 / CXCL-2 gradients 
To investigate the tumor microenvironment of CT26 solid tumors, immune histology of 
paraffin-embedded tumors as well as luminex analyses of tumor lysates were deployed. 
The analysis of consecutive tumor sections revealed the presence of a large number of 
tumor-associated neutrophils between the viable and the necrotic tumor zone within the 
colonized tumor tissue. The attraction of neutrophils to the inflammatory side was 
possibly influenced by PDGF-bb in combination with the detected cytokines TNF-α and 
VEGF.  
Discussion 71 
 
Due to the function of these molecules, the vascular permeability of the tumor-associated 
blood vessels might have been increased and consequently enabled a strong influx of 
neutrophils into the tumor microenvironment. 
The combined illustration of the chemokine concentrations in blood samples and tumor 
lysates revealed the presence of only one chemokine gradient in infected mice able to 
recruit neutrophils into tumors. This was the concentration gradient of MIP-2 / CXCL-2. 
Malignant- as well as stromal cells of the tumor microenvironment are described to 
secrete the cytokine [148] and thus might have been responsible for the increased 
concentration of MIP-2 in the tumor tissue. Thereby, this chemokine could have triggered 
the extravasation of neutrophils into infected tumors. This would be in accordance with a 
previous study, which highlighted the importance of MIP-2 for the recruitment of 
neutrophils into necrotic tumor areas [165]. TANs inside untreated tumors could have 
been influenced by the neutrophil chemoattractants KC / CXCL-1, MCP-1 / CCL-2, MIP-
1α / CCL-3, or Rantes / CCL-5 in addition to infiltrate the tumor tissues. Also these 
cytokines are reported to be secreted by malignant- as well as stromal cells [22, 51, 149, 
150]. Hence these cells could have caused the increased availability of the molecules 
inside such tumor microenvironments. But even though five chemokine gradients for the 
possible attraction of neutrophils were detected in untreated tumors, the total number of 
TANs was decreased compared to colonized tumors. Whether the decreased amount of 
MIP-2 in uninfected tumors might be responsible for that, could be investigated by 
applying recombinant MIP-2 into tumor bearing mice in future experiments. 
However, also further chemokines like CXCL-5 / ENA-78 (epithelial neutrophil activating 
peptide-78) or CXCL-12 / SDF-1 (stromal cell-derived factor 1), which were not included in 
the present study, might have influenced the infiltration of neutrophils into tumors. This 
was demonstrated in recent studies of our group [48, 69]. Thus this study should be 
extended to concentrations of CXCL-5 or CXCL-12 inside P. aeruginosa infected CT26 
tumors. For that, enzyme-linked immunosorbent assays of tumor lysates could be 
performed. To test furthermore whether tumor-associated neutrophils generally respond 
to a certain chemokine gradient, the receptor for the chemokine of interest could be 
blocked on neutrophils prior to infection, or the establishment of the respective cytokine 
gradient could be manipulated by the application of specific antibodies. 
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4.4 TANs change their phenotypes to N1 after infection or TNF-α treatment 
Since the functional specialization of TANs is supposed to be influenced by the various 
conditions within the tumor microenvironment, the impact of a systemic infection with 
the P. aeruginosa WT strain PA14 on the phenotype of the TAN population was 
investigated. Recombinant TNF-α was applied as a control group to distinguish the impact 
of a common necrotic tumor region from the effects of a necrotic core which might 
include bacterial colonization. Because the definitions of N1- and N2-phenoytpes are only 
end-stage descriptions, the present study rather described the changes of single 
phenotypic markers than determining gross population-phenotypes under the respective 
conditions in the tumor. Thus, not all markers analyzed had to be up- or downregulated at 
a time to indicate a certain phenotypic switch. 
First of all, the total number of TANs per gram tumor tissue was compared between PBS-, 
PA14-, and TNF-α-treated tumor-bearing BALB/c -WT or -Rag1-/- mice. Here, the number 
of TANs was generally increased after PA14- or TNF-α injection. Additionally, a phenotypic 
switch of the whole TAN population to a stronger tumor-suppressive N1 phenotype was 
demonstrated after P. aeruginosa infection and to a less extent after TNF-α treatment. 
This was characterized by individual numbers of increased percentages of TANs expressing 
certain pro-inflammatory markers. Thus, the responses of TANs seemed to be not specific 
for bacterial PAMPs like LPS or flagellin, rather than induced by a general boost of pro-
inflammatory molecules within the tumor microenvironment. 
In infected tumor-bearing mice, the N1-inducing cytokine IFN-β was strongly secreted by 
the host cells. Hence, the detected phenotypic switches after infection, especially the 
general up-regulations of Icam, Fas and active caspase 3 in a high number of TANs, could 
have been induced by IFN-β. This would be in accordance with a new study from our lab, 
in which we revealed the partial dependency of Icam, Fas, and active caspase 3 expression 
by TANs on IFN-β in another tumor model [75]. Thus, in the present study the increased 
secretion of IFN-β seemed to be dependent on the bacterial stimulus, since the induced 
extrinsic inflammatory effects by the application of recombinant TNF-α did not trigger an 
endogenous IFN-β-response in the host. 
On the other hand, the concentration of the six neutrophil polarizing cytokines analyzed, 
especially of G-CSF and MCP-1 / CCL-2, were decreased after infection. G-CSF and MCP-1 
have been reported to influence the lifetime of neutrophils [151, 152]. Therefore, a 
decreased concentration of such cytokines might have favored a prolonged lifespan of 
TANs inside the tumors, and thereby increased the chances for phenotypic switches back 
to a tumor-suppressive N1 phenotype. 
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Since the corresponding luminex analyses and the in vivo-imaging of IFN-β reporter mice 
were performed on tumors from WT mice only, similar contributions of the cytokines on 
neutrophil infiltration and phenotypes within Rag1-/- mice can solely be assumed. 
The percentage of TANs with a tumorigenic N2 phenotype was generally higher in PBS-
treated control tumors with broadened hypoxic islands compared to tumors with few 
hypoxic areas but large necrotic regions like after injection of P. aeruginosa or 
recombinant TNF-α. Therefore, it might be possible that the sustained development of 
tumor-supporting N2 TANs was favored by the increased hypoxic conditions inside PBS-
treated tumors of WT- and Rag1-/- mice to promote the ongoing tumor growth. The 
activation of the transcription factor HIF-1α is described to be necessarily induced in cells 
surviving under hypoxic conditions and to trigger tumor-supportive N2 functions in 
CD11b+ Gr1+ cells in addition [30]. HIF-1α is for example supposed to decrease the 
production of ROS in TANs or to favor the prolongation of the lifetime of such cells [153, 
154]. Future experiments could analyze ROS production in tumor-bearing WT- or Rag1-/- 
mice by first applying luminol (5-amino-2,3-dihydro-1,4-phthalazine-dione) into the mice 
to visualize the concentration of ROS produced by immune cells using live in vivo imaging 
[155, 156]. In a second step, consecutive tumor sections could be stained for neutrophils, 
H&E, hypoxia, and ROS to determine the exact localization of ROS-producing TANs. For the 
latter, a polyclonal rabbit-anti-ROS1 antibody (Novus Biologicals, USA) or several other 
antibodies detecting protein- or lipid oxidations [157] may be used. In tumors of infected 
or TNF-α-treated WT- and Rag1-/- mice, the area of hypoxic tumor zones was dramatically 
decreased. As a consequence, the concentration of HIF-1α inside TANs and further cells 
within the tumor microenvironment might have been reduced. A recent study 
demonstrated an increased tumor rejection rate in such tumor-bearing mice, whose 
BMDCs were deficient for HIF-1α [30]. To show an impact of HIF-1α on the functional 
phenotypes of TANs in our model, tumor-bearing BALB/c mice deficient for HIF-1α might 
be tested. 
All in all, the observed phenotypic switches from N2 to N1 TANs inside tumors of mice 
injected with P. aeruginosa or recombinant TNF-α might have been induced either by a 
reduction of hypoxia, or by an increased availability of certain pro-inflammatory molecules 
in such tumor microenvironments. In addition, components of the necrotic cells could 
have been involved. However, the availability of these pro-inflammatory triggers strongly 
affected the production of the N1-inducing cytokine IFN-β only in infected tumor-bearing 
mice. Based on these observations, it is supposed that endogenous IFN-β alone is not 
responsible for the phenotypic switches from tumor-supportive N2 to tumor-suppressive 
N1 TANs in the present study.  
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4.5 TANs might induce P. aeruginosa biofilm formation in oxic tumor areas 
In tumors of PBS-treated mice (data not shown) as well as in infected tumors, tumor-
infiltrated neutrophils resided between hypoxic islands and the necrotic tumor core. 
Under such hypoxic to anoxic conditions, the lifespan of neutrophils was described to be 
increased [156], because the cells are able to adapt their metabolism to the low oxygen 
concentrations. Also for that they stabilize the transcription factor HIF-1α, which induces a 
metabolic switch from oxidative phosphorylation to glycolysis [157]. Thus, TANs are 
supposed to be very resistant and functional under low oxygen levels [158]. In respect to 
our solid tumor model, the localization of TANs in hypoxic areas close to the necrotic 
tumor center obviously represented the most favorable niche for such cells.  
Especially in the context of their assumed anti-tumor functions [40, 47, 158], the 
additional detection of TANs within the zone of viable tumor cells is reasonable. Since 
TANs are pro-inflammatory phagocytic cells, their localization close to P. aeruginosa was 
expected. Likewise, the appearance of bacterial clusters embedded in biofilm material 
inside tumors from WT mice was published by our group recently [139]. Nevertheless, the 
previous study suggested a connection between functions of the adaptive immune system 
and in vivo biofilm formation by the P. aeruginosa WT strain PA14 [124]. However, the 
present study demonstrated that PA14 in vivo biofilm formation was independent of the 
presence of the adaptive immune system. A huge amount of such bacterial matrix 
material was detected around PA14 clusters in the viable zone of tumors on 
immunocompromised Rag1-/- mice. Therefore the occurrence of T- or B cells is apparently 
not crucial for the development of PA14 biofilms in the present model. As the evidence for 
biofilm production is derived from electron microscopical analysis, the biofilms formed by 
PA14 in tumors of Rag1-/- mice might have simply been missed in the previous study. 
Since neutrophils were co-localized with bacterial clusters inside the tumors from WT- and 
Rag1-/- animals, it is proposed that the bacteria produced the energy-costly extracellular 
biofilm material to protect themselves from antimicrobial- and phagocytic functions of 
TANs. The direct effect of neutrophils on P. aeruginosa in vivo biofilm formation could not 
be tested, since WT mice did not survive the infection after neutrophil depletion (results 
not shown). Future investigations using different histological techniques might figure out, 
if the increased concentration of oxygen in the viable tumor zone influences the 
antimicrobial activity of TANs, and whether such cells show a rather N1 phenotype 
compared to TANs within the hypoxic tumor area. 
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4.6 Concluding remarks and future investigations 
Immunocompetent WT mice bearing CT26 tumors were i.v. infected with the 
P. aeruginosa WT strain PA14. This activated tumor specific effector CD4+- and CD8+ 
T cells. The CTLs were able (i) to reject tumors when present in sufficient numbers, and (ii) 
to generate a functional and tumor-specific T cell memory able to suppress the 
development of new CT26 tumors. The present study demonstrated furthermore, that 
tumor-suppressive N1 phenotypes of tumor-associated neutrophils were successfully 
induced in tumor-bearing mice by the i.v. infection with P. aeruginosa. The strongest 
phenotypic switch of the TAN population was detected in Rag1-/- mice three days p.i. 
Nonetheless, such tumor-bearing mice were not able to reject tumors in contrast to 
infected WT animals due to their immune deficiency.  
The ability of TANs to adapt to highly diverse conditions and to fulfill tumor-suppressing 
functions are new promising tools for cancer immunotherapies. The actual literature 
already describes possibilities of applications of N1 TANs in tumor therapy based on their 
reduced secretion of arginase and a consequently reduced suppression of T cells within 
tumor microenvironments [75], and their increased production of ROS, by which N1 TANs 
might be able to kill tumor cells directly [159]. Thus, bacteria-mediated tumor therapy 
might represent a promising strategy to control the functional specialization of TANs 
inside tumor microenvironments and to induce phenotype switches from N2 to N1. Since 
the type I interferon IFN-β that was believed to be responsible for the N1 phenotype was 
not exclusively in charge of these phenotypic switches in the present study, further 
investigations should aim at describing additional cytokines or conditions within tumor 
microenvironments which induce tumor-suppressive N1 TANs. 
Our solid tumor model would enable such future investigations as well as experiments to 
detect additional pro-inflammatory triggers which favor the development of N1 TANs. 
Besides that, further molecules important for the recruitment of neutrophils into tumors, 
signaling pathways inside TANs leading to the induction of pro-inflammatory phenotypes, 
additional anti-tumor mechanisms of N1 TANs, as well as possible interaction partners of 
the cells might be characterized in vivo. Moreover, screenings for intervention strategies 
against the development of tumor-suppressive microenvironments are issues which might 
be addressed. The use of syngeneic mouse lines will allow analyses in defined 
immunocompromised hosts and the characterization of important effector cells and 
molecules under standardized conditions.  
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5 Abstract 
In the present work, first parameters important for the optimal colonization of tumors by 
Pseudomonas aeruginosa were established. The optimal tumor volume and the 
concentration of the bacterial inoculum for the infection of tumor-bearing BALB/c wild-
type (WT) mice was determined. Apparently, CT26 tumors need to develop for ten days to 
guarantee a qualified colonization of the tumor tissue. Moreover, the infection dose of 
5x106 P. aeruginosa was suitable for intravenous (i.v.) infections of tumor-bearing mice, 
resulting in a high and reproducible colonization of the subcutaneous tumor. The use of 
these newly determined parameters resulted in minimal burden for the mice, which 
allowed further experimentation due to animal survival of infection and tumor clearance.  
Since the i.v. application of the bacteria lead to tumor clearance in WT mice, the quality of 
differentially primed CD4+- and CD8+ T cells to specifically act against tumor cells was 
investigated by adoptive transfer experiments in syngeneic Rag1-/- animals. Interestingly, 
T cells isolated from uninfected tumor-bearing WT mice achieved the complete rejection 
of new tumors, when a combination of CD4+ + CD8+ T cells was injected into the recipient 
mice. This demonstrated that also uninfected tumor-bearing mice contain tumor-antigen 
specific T cells, which are nevertheless not able to reject such tumors. The adjuvant effect 
of the bacteria that activates the tumor-specific T cells seemed to be necessary to enable 
tumor clearance in WT animals. On the other hand, when T cells were isolated out of WT 
mice which had cleared CT26 tumors after infection with P. aeruginosa, the application of 
CD8+ T cells alone prevented the development of tumors on modified Rag1 mice. By that, 
the development of a T cell memory and functional specificity was revealed.  
The impact of the bacterial infection on functional specializations of tumor-associated 
neutrophils (TANs) in the tumor microenvironment was investigated. To this end, the 
expression of the extracellular phenotypic markers Icam, Fas, and CD62L, as well as the 
production of the intracellular markers TNF-α and active caspase 3 was determined. The 
analyses revealed phenotype switches of the respective TAN population from N2 to N1 
after the i.v. injection of P. aeruginosa into tumor-bearing WT- as well as Rag1-/- mice. The 
most and maximal significant changes of the percental number of TANs expressing a 
certain phenotypic marker were observed three days post infection of tumor-bearing 
Rag1-/- mice. By the application of P. aeruginosa into tumor-bearing mice, tumor-
supportive N2 TANs were obviously forced to switch to tumor-suppressing N1 TANs. Now, 
defined functions of N1 TANs can be investigated in future experiments and their onset in 
the present model probably induced by the bacteria-mediated tumor therapy. 
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6 Zusammenfassung 
Eine Intension der Arbeit war es wichtige Parameter für die optimale Kolonisierung von 
Tumoren durch Pseudomonas aeruginosa herauszufinden. Dazu wurde das optimale 
Tumorvolumen und die effizienteste Konzentration des bakteriellen Inokulums am Tag der 
Infektion von tumortragenden BALB/c Wildtyp (WT) -Mäusen etabliert. Offensichtlich 
müssen sich syngene CT26 Tumore über zehn Tage entwickeln, um eine qualifizierte 
Kolonisierung des Tumorgewebes durch die Bakterien zu garantieren. Darüber hinaus war 
eine Infektionsdosis von 5x106 P. aeruginosa für intravenöse (i.v.) Infektionen von 
tumortragenden Mäusen optimal, da sie in einer hohen und reproduzierbaren 
Kolonisierung der subkutanen Tumore resultierte. Die Anwendung der neu bestimmten 
Parameter resultierte darüber hinaus in einer minimalen Belastung für die Tiere, was ihr 
Überleben nach der Infektion und die komplette Eradizierung des Tumors ermöglichte. 
Da die i.v. Anwendung der Bakterien in einer Beseitigung der Tumore in WT-Mäusen 
resultierte, wurden CD4+- und CD8+ T-Zellen aus derartigen Mäusen, durch adoptive 
Transferexperimente in syngene Rag1-/- Mäuse untersucht. Interessanterweise 
ermöglichten T-Zellen, die aus uninfizierten CT26 tumortragenden WT-Mäusen isoliert 
wurden, eine komplette Abstoßung neuer CT26 Tumore, wenn eine Kombination aus 
solchen CD4+- + CD8+ T-Zellen in die Rezipienten-Mäuse injiziert wurde. Dadurch wurde 
gezeigt, dass auch uninfizierte tumortragende Mäuse Tumorantigen-spezifische T-Zellen 
besitzen, die allerdings nicht dazu fähig sind bereits ausgebildete Tumore zu beseitigen. 
Der adjuvante Effekt der applizierten Bakterien erscheint für eine solche Beseitigung von 
Tumoren in WT-Mäusen notwendig zu sein. Allerdings, wenn T-Zellen aus solchen WT-
Mäusen isoliert wurden, welche die Tumore nach der Infektion mit P. aeruginosa beseitigt 
hatten, war die Anwendung von ausschließlich CD8+ T-Zellen ausreichend, um die 
Entwicklung von Tumoren in den modifizierten Rag1-Mäusen zu verhindern. Dadurch 
konnte das Bestehen von Gedächtnis-T-Zellen und deren funktionelle Spezifität bestätigt 
werden. 
Ebenfalls wurde der Einfluss der bakteriellen Infektion auf die funktionelle Spezialisierung 
von Tumor-assoziierten Neutrophilen (TANs) im Tumormikromilieu untersucht. Dazu 
wurde die Expression der extrazellulären Phänotypisierungsmarker Icam, Fas und CD62L, 
sowie die Produktion der Zytokine TNF-α und aktive Caspase 3, die als intrazelluläre 
Phänotypisierungsmarker analysiert wurden, bestimmt. Die Analysen zeigten einen 
Phänotyp-Wechsel der jeweiligen TAN-Population von N2 zu N1 nach der i.v. Injektion von 
P. aeruginosa in tumortragenden WT- als auch Rag1-/--Mäusen an.  
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Die meisten und maximal signifikanten Veränderungen der prozentualen Anzahl an TANs, 
die einen bestimmten Phänotyp-Marker exprimierten, wurden drei Tage nach der 
Infektion von tumortragenden Rag1-/- Mäusen festgestellt. Aufgrund der Verwendung von 
P. aeruginosa in tumortragenden Mäusen wurden Tumor-unterstützende N2 TANs 
offensichtlich dazu gebracht sich in Tumor-hemmende N1 TANs umzuwandeln. Folglich 
können bestimmte Funktionen von N1 TANs in zukünftigen Experimenten untersucht und 
ihre Aktivierung mittels der Bakterien-vermittelten Tumortherapie induziert werden, ein 
möglicher Vorzug dieser Therapie.  
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